WO2005117895A2 - Compositions comprising meloxicam - Google Patents

Compositions comprising meloxicam Download PDF

Info

Publication number
WO2005117895A2
WO2005117895A2 PCT/EP2005/005747 EP2005005747W WO2005117895A2 WO 2005117895 A2 WO2005117895 A2 WO 2005117895A2 EP 2005005747 W EP2005005747 W EP 2005005747W WO 2005117895 A2 WO2005117895 A2 WO 2005117895A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
pain
composition according
meloxicam
active compound
Prior art date
Application number
PCT/EP2005/005747
Other languages
French (fr)
Other versions
WO2005117895A8 (en
WO2005117895A3 (en
Inventor
Toshiaki Horie
Minoru Okada
Hiroshi Otaki
Norimitsu Umehara
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to JP2007513820A priority Critical patent/JP2008501655A/en
Publication of WO2005117895A2 publication Critical patent/WO2005117895A2/en
Publication of WO2005117895A8 publication Critical patent/WO2005117895A8/en
Publication of WO2005117895A3 publication Critical patent/WO2005117895A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

  • compositions comprising meloxicam
  • This invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising meloxicam or a pharmaceutically acceptable salt thereof and at least a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs.
  • an oral pharmaceutical dosage form comprising such a composition.
  • a further objective of this invention is related to the use of the composition and the oral pharmaceutical dosage form.
  • this invention relates to the use of meloxicam and at least a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs for the manufacture of such an oral pharmaceutical dosage form.
  • this inventions relates to a method of treating or alleviating of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as fever, pyrexia, arthralgia, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
  • COX inhibitors which nonspecifically inhibit cyclooxygenase (COX), a rate-limiting enzyme for biosynthesis of prostaglandin (PG) from arachidonic acid. Inhibition of COX contributes to anti-inflammatory, analgesic and antipyretic effects by inhibiting production of PGE 2 , on the other hand, it also causes adverse drug reactions such as digestive disorders and renal disorders.
  • COX includes two types of isoforms, i.e. COX-1 and COX-2.
  • COX-1 is constitutively (a certain amount of protein is developed regardless of proliferation or environmental changes) developed in most of the organs such as stomach and kidneys.
  • COX-2 is induced by various inflammatory mediators or endotoxin in local inflammatory areas.
  • Meloxicam is a known selective COX-2 inhibitor.
  • Oral administration of a selective COX-2 inhibitor still may, however, cause some side effects in the digestive system such as stomach indisposition and stomachache.
  • oral pharmaceutical compositions with strengthened efficacy and superior safety by increasing anti-inflammatory, analgesic and antipyretic effects, while alleviating side effects such as gastrointestinal disorders are desired.
  • a combination of an inhibitor of nitric oxide synthase for treatment of inflammation and inflammatory diseases and a COX-2 inhibitor for treatment of inflammation-related diseases is disclosed in the specification of International Publication WO 99/18960.
  • a combination of a COX-2 inhibitor and a leukotriene B4 receptor antagonist as effective for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication WO 96/41645.
  • a combination of a COX-2 inhibitor and a 5-lipoxygenase inhibitor as effective for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication W096/41626.
  • a composition comprising a COX-2 inhibitor and a leukotriene A4 hydroxylase inhibitor for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication WO 96/41625.
  • a pharmaceutical composition comprising a COX-2 inhibitor and opioid analgesics as a method to increase efficacy of meloxicam is disclosed in the specification of the international publication WO 99/13799.
  • a pharmaceutical composition comprising morphine and meloxicam in the ratio of 1 :10 is disclosed therein. Such a composition is, however, unfavorable for safety reasons since opioid may cause undesirable side effects.
  • the aim of the present invention is to further improve the safety profile of meloxicam with respect to possible side effects and to provide a pharmaceutical composition and an oral pharmaceutical dosage form comprising meloxicam and having improved anti-inflammatory, analgesic and antipyretic effects.
  • the present invention aims to provide highly safe oral pharmaceutical compositions comprising meloxicam with more improved anti-inflammatory, analgesic and antipyretic effects.
  • a further objective of this invention is to provide more effective pharmaceutical compositions for the treatment of a cold with improved efficacy and safety.
  • a further aim of this invention is to provide a method of treating or alleviating inflammatory diseases, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, fever, and the like.
  • a further aim of this invention is to provide a method of treating or alleviating of a cold, including various symptoms thereof, such as sore throat, fever, chills, headache, runny nose, stuffy nose, sneezing, cough, phlegm, joint pain, muscular pain and the like.
  • This invention relates to new pharmaceutical compositions comprising meloxicam or a pharmaceutically acceptable salt thereof and and a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs.
  • meloxicam or the salt thereof is present in an effective amount allowing itself to exert anti-inflammatory, analgesic and antipyretic effects.
  • An advantage of the present invention is that the composition of the invention allows a reinforcement of the therapeutic effects such as analgesic, anti-inflammatory and antipyretic effects without the need to increase. the dose of meloxicam. It is possible to provide pharmaceutical compositions as oral pharmaceutical dosage forms with improved efficacy and safety. Possible side effects of common NSAIDs, as e.g. gastrointestinal disorders, are avoided or alleviated by using meloxicam.
  • composition of the present invention is especially suitable for the treatment or alleviation of inflammatory disease and to alleviate its symptoms such as headache, toothache, menstrual pain, sore throat, joint pain, muscle pain, neuralgia, lumbago, stiff shoulder, tooth extraction pain, contusion pain, earache, fracture pain, sprain pain, traumatic pain, chill and/or fever.
  • composition of the present invention is especially suitable for the treatment or alleviation of common cold and to alleviate its symptoms such as fever, sore throat, chills, headache, joint pain muscular pain and/or phlegm.
  • the improved safety profile enables the use of such compositions in non-prescription drugs.
  • Meloxicam is a known selective COX-2 inhibitor which belongs to the acid enolcarboxamide (oxicam) type of non-steroidal anti-inflammatory drugs (NSAIDs).
  • NSAIDs non-steroidal anti-inflammatory drugs
  • the compound (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H1 ,2-benzothiazine- 3-carboxamide 1 ,1 -dioxide) is described in EP 0 002 482 B1 and US 4,233,299.
  • the invention may employ either meloxicam itself or a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable salt of meloxicam includes sodium salt, potassium salt, ammonium salt, meglumine salt, tris salt, and salts of meloxicam with a basic amino acid as examples.
  • Various salts of meloxicam are described in EP 0 002482 B1 , US 4,233,299 and WO 99/49867.
  • the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins.
  • compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent and/or an expectorant.
  • pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent and/or an expectorant.
  • an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
  • a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam.
  • a reinforcement of analgesic By using a sedative as a further ingredient a reinforcement of analgesic, anti-inflammatory and antipyresis therapeutic effect is obtainable.
  • an antitussive agent By using an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
  • an expectorant By using an expectorant an additional alleviation of symptoms of common cold, like e;g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
  • common cold like e;g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum.
  • a pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one antacid.
  • This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antitussive agent, one or more, preferably one expectorant and/or one or more, preferably one sedative.
  • a further pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one central nervous system stimulant.
  • This composition may additionally comprise one or more, preferably one antacid, one or more, preferably one antitussive agent, one or more, preferably one expectorant and/or one or more, preferably one sedative.
  • compositions according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one antitussive agent.
  • This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one expectorant and/or one or more, preferably one sedative.
  • compositions according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one expectorant.
  • This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one or two antitussive agents and/or one or more, preferably one sedative.
  • compositions according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one sedative.
  • This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one expectorant and/or one or more, preferably one or two antitussive agents.
  • the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more antiphlogistic drugs.
  • compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin and/or an anti-H1-histamine.
  • a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant and/or a vitamin.
  • a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin and/or an anti-H1-histamine.
  • pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin and/or an anti-H1-histamine.
  • an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
  • a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam.
  • an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
  • an expectorant By using an expectorant an additional alleviation of symptoms of common cold, like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
  • common cold like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum.
  • an anti-H1-histamine as a further ingredient an alleviation of symptoms of common cold such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose and/or sneezing is obtainable.
  • the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more crude drugs.
  • compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-H1-histamine and/or an antiphlogistic agent.
  • pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-H1-histamine and/or an antiphlogistic agent.
  • a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, a vitamin and/or an antiphlogistic agent.
  • pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, a vitamin and/or an antiphlogistic agent.
  • a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-Hi -histamine and/or an antiphlogistic agent.
  • pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-Hi -histamine and/or an antiphlogistic agent.
  • an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
  • a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam.
  • an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
  • an expectorant By using an expectorant an additional alleviation of symptoms of common cold, like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
  • common cold like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum.
  • a reinforcement of therapeutic effects such as analgesic, anti-inflammatory and antipyretic effects is obtainable.
  • an anti-H1-histamine as a further ingredient an alleviation of symptoms of common cold such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose and/or sneezing is obtainable.
  • compositions according to this invention may comprise one or more vitamins as a second or further active ingredient in addition to meloxicam.
  • vitamin includes vitamins as such, vitamin-like substances and salts and derivatives of vitamins and of vitamin-like substances.
  • compositions in the present invention may comprise one, two, three or more vitamins, which preferably are selected from the group consisting of vitamin B1 , vitamin B2, vitamin C and/or hesperidin, including salts, in particular pharmaceutically acceptable salts, and derivatives thereof.
  • Vitamin B1 used in the present invention is preferably selected from the group consisting of thiamine, thiamine hydrochloride, thiamine nitrate, thiamine disulfide nitrate, thiamine disulfide, thiamine dicetylsulfate salt, dicethiamine hydrochloride, fursultiamine hydrochloride, fursultiamine, octotia ine, cycotiamine, bisibutiamine, bisbentiamine, prosultiamine, benfotiamine, cocarboxylase, dibenzoylthiamaine, etc.
  • Vitamin B2 used in the present invention is preferably selected from the group consisting of riboflavin, riboflavin butyrate, riboflavin sodium phosphate, flavin adenine dinucleotide, etc.
  • Vitamin C used in the present invention is preferably selected from the group consisting of ascorbic acid, sodium ascorbate, calcium ascorbate, etc.
  • Hesperidin used in the present invention is preferably selected from the group consisting of hesperidin, alpha G hesperidin, etc.
  • compositions according to this invention may comprise one or more antiphlogistic agents as a second or further active ingredient in addition to meloxicam.
  • the one or more antiphlogistic agents used in the present invention is preferably selected from the group consisting of semi-alkaline proteinase, serrapeptase, bromelain and tranexamic acid.
  • One of these antiphlogistic agents can be used in combination with meloxicam or a combination of two or more of these antiphlogistic agents can be used together with meloxicam.
  • compositions according to this invention may comprise one or more crude drugs as a second active ingredient in addition to meloxicam.
  • the one or more crude drug used in the present invention is preferably selected from the group consisting of earthworm (Lumbricus), cinnamon bark (Cinnamomi cortex), peony root (Paeoniae radix), moutan bark (Moutan cortex), Japanese valerian (Velerianae radix) , zanthoxylum fruit (Zanthoxylifi'uctus), ginger (Zing ⁇ beris rhizoma), citrus unshiu peel (Aurantii nobilis pericarpium), fennel (Foeniculi fructus), phellodendron bark (Phellodendri cortex), coptis rhizome (Coptidis rhizoma), zedoary (Zedoariae rhizoma), German chamomile (Chamomillaflos), gentian (Gentianae radix), oriental bezoar (Bezoar bovis), bear bile (Fel ursi), fourlea
  • the one or more crude drugs are selected from the group consisting of earthworm, cinnamon bark, peony root, Japanese valerian, ginger, fennel, phellodendron bark, coptis rhizome, German chamomile, gentian, oriental bezoar, ginseng, scutellaria root, pueraria root, apricot kernel, jujube.
  • crude drug can be in the form of a dried powder, an extract, a fluidextract, a tincture, an oil or other kind of preparations known to the one skilled in the art.
  • the crude drug is a formulation according to the Kampo medicine.
  • Kampo medicine formulations are described in 2004-5 Drug in Japan : OTC-Drugs (edited by Japan Pharmaceutical Information Center, issued by Yakuji Nippo, Ltd.).
  • Preferred examples of Kampo medicine formulations are kakkon-to, keishi-to, kouso-san, saiko-keishi-to, sho-saiko-to, sho-seiryu-to, bakumondo-to, hange-koboku-to and mao-to.
  • the preferred contents of the Kampo medicine formulations as mentioned above is given.
  • Kakkon-to is an extract of the crude drugs pueraria root, glycyrrhiza, cinnamon bark, peony root, ginger, ephedra herb and jujube, preferably of the approximate ratios 8 : 2 : 3 : 3 : 1 : 4 : 4 by weight.
  • Keishi-to is an extract of the crude drugs glycyrrhiza, " cinnamon bark, peony root, ginger and jujube, preferably of the approximate ratios 2 : 4 : 4 : 1 : 4 by weight.
  • Kouso-san is an extract or a powder of the crude drugs glycyrrhiza, ginger, citrus unshiu peel, cyperus rhizome and perilla herb, preferably of the approximate ratios 1 : 1 : 3 : 4 : 2 by weight.
  • Saiko-keishi-to is an extract of the crude drugs glycyrrhiza, cinnamon bark, peony root, ginger, ginseng, scutellaria root, bupleurum root, jujube and pinellia tuber, preferably of the approximate ratios 2 : 3 : 3 : 1 : 2 : 2 : 5 : 2 : 4 by weight.
  • Sho-saiko-to is an extract of the crude drugs glycyrrhiza, ginger, ginseng, scutellaria root, bupleurum root, jujube and pinellia tuber, preferably of the approximate ratios 2 : 1 : 3 : 3 : 7 : 3 : 5 by weight.
  • Sho-seiryu-to is an extract of the crude drugs glycyrrhiza, cinnamon bark, peony root, ginger, ephedra herb, schisandra fruit, asiasarum root and pinellia tuber, preferably of the approximate ratios 2 : 3 : 3 : 2 : 3 : 3 : 5 by weight.
  • Bakumondo-to is an extract of the crude drugs glycyrrhiza, ginseng, rice, jujube, ophiopogon tuber and pinellia tuber, preferably of the approximate ratios 2 : 2 : 10 : ' 3 : 8 : 5 by weight.
  • Hange-koboku-to is an extract of the crude drugs ginger, magnolia bark, perilla herb, pinellia tuber and poria sclerotium, preferably of the approximate ratios 1 : 3 :
  • Mao-to is ah extract of the crude drugs glycyrrhiza, cinnamon bark, ephedra herb and apricot kernel, preferably of the approximate ratios 2 : 3 : 4 : 4 by weight.
  • antacids are aminoacetic acid, synthetic aluminum silicate, hydrotalcite, magnesium oxide, dihydroxy aluminum aminoacetate, aluminum hydroxide gel, dried aluminum hydroxide -gel, aluminum hydroxide-sodium bicarbonate co-precipitate, magnesium carbonate, magnesium aluminometasilicate, magnesium hydroxide, sodium hydrogencarbonate and calcium hydrogenphosphate and the like.
  • Suitable sedatives are allylisopropylacetylurea and bromvalerylurea and the like.
  • Suitable central nervous system stimulants are caffeine (3,7-dihydro-1 ,3,7-trimethyl-1 H-purine-2,6-dione monohydrate), anhydrous caffeine (3,7-dihydro-1 ,3,7-thmethyl-1 H-purine-2,6-dione) and a salt complex of caffeine and sodium benzoate (caffeine and sodium benzoate) and the like. Also combinations of two or more central nervous system stimulants may be used.
  • Suitable antitussive agents are tipepidine citrate, tipepidine hibenzate, dextromethorphan hydrobromide, codeine phosphate, dihydrocodeine phosphate, noscapine hydrochloride, noscapine, dl-methyiephedrine hydrochloride, dimemorfan phosphate, ephedra herb, nandina fruit and the like. More preferably the one or more antitussive agents are selected from the group consisting of tipepidine citrate, dextromethorphan hydrobromide, dihydrocodeine phosphate, hoscapine hydrochloride, noscapine, and dl-methylephedrine hydrochloride. These antitussive agents can be used solely or mixed with more than two kinds.
  • Suitable expectorants are potassium guaiacolsulfonate, guaifenesin, bromhexine hydrochloride, ambroxol hydrochloride, L-carbocisteine, ethyl L-cysteine hydrochloride, fudosteine, platycodon root, glycyrrhiza, cherry bark, polygala root, plantago seed, plantago herb, lycoris bulb, senega, fritillary bulb and the like. More preferably the one or more expectorants are selected from the group consisting of guaifenesin, bromhexine hydrochloride, ambroxol hydrochloride, L-carbocisteine and fudosteine.
  • Examples of preferred anti-H1-histamines are diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tannate, diphenylpyraline hydrochloride, diphenylpyraline teoclate, clemastine fumarate, triprolidine hydrochloride, promethazine hydrochloride, promethazine methylenedisalicylate, alimemazine tartrate, isothipendyl hydrochloride, iproheptine hydrochloride, difeterol hydrochloride, difeterol phosphate, tripeiennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, mebhydroline napadisylate, mequitazine, ketotifen fumarate, epinastine hydrochloride, chlorpheniramine maleate, carbinoxamine maleate and the
  • the pharmaceutical composition according to this invention further comprises at least one pharmaceutically acceptable carrier and/or excipient.
  • suitable carriers and excipients are known to the one skilled in the art and are described for example in Japanese Pharmaceutical Excipients Directory 2000 (edited by Japan Pharmaceutical Excipients Council, issued by Yakuji Nippo, Ltd.).
  • suitable carriers and/or excipients are lactose, sucrose, glucose, mannitol, xylitol, corn starch, potato starch, wheat starch, rice starch, tapioca starch, sodium carboxymethyl starch, microcrystalline cellulose, ethylcellulose, hydroxypropylmethylcellulose, low substituted hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium, carmellose, carmellose potassium, carmellose calcium, carmellose sodium, polyvinylpyrrolidone, propyleneglycol, polyethyleneglycol, glycerol, vegetable oils, waxes, crospovidone, agar, light anhydrous silicic acid, magnesium stearate, talc, titanium oxide, acacia, sodium alginate, ethanol and purified water.
  • this invention relates to a pharmaceutical dosage form which comprises a pharmaceutical composition according to this invention.
  • the amount of meloxicam or of a salt thereof used for the oral pharmaceutical dosage form described in the invention is preferably in the range from 1 to 30 mg, more preferably in the range from 2.5 to 15 mg, and most preferably in the range from 5 to 10 mg. These amounts correspond to the preferred dosage ranges with respect to an adult and once daily given dose.
  • the at least one second pharmaceutically active compound is selected from the group consisting of vitamins.
  • the amount of the one or more vitamins in the oral pharmaceutical dosage form according to the present invention may be varied depending on the type of the vitamin. It preferably lies in the range from 0.1 to 2000 mg, and more preferably . in the range from 0.1 to 500 mg. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called “daily combination dosage") of suitable vitamins comprised in a composition according to this invention are specified.
  • the daily combination dosage of vitamin B1 for an adult is usually about 0.1 to 100 mg, preferably 0.5 to 50 mg, and more preferably 1 to 25 mg.
  • the daily combination dosage of vitamin B2 for an adult is usually about 0.1 to 45 mg per day, preferably 1 to 30 mg, and more preferably 2 to 12 mg.
  • the daily combination dosage of vitamin C for an adult is usually about 5 to 2000 mg per day, preferably 25 to 1000 mg, and more preferably 50 to 500 mg.
  • the daily combination dosage of hesperidin for an adult is usually about 1 to 270 mg per day, preferably 9 to 180 mg, and more preferably 18 to 90 mg.
  • the at least one second pharmaceutically active compound is selected from the group consisting of antiphlogistic agents.
  • the amount of the one or more antiphlogistic agents in the oral pharmaceutical dosage form according to the present invention may be varied depending on the type of the antiphlogistic agent. It preferably lies in the range from 1 to 2000 mg, and more preferably in the range from 3 to 750 mg. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called “daily combination dosage") of suitable antiphlogistic agents comprised in a composition according to this invention are specified.
  • the daily combination dosage of semi-alkaline proteinase for an adult is usually between 2 and 60 mg (4000 and 120000 units), preferably between 4 and 45 mg (8000 and 90000 units), more preferably between 6 and 30 mg (12000 units and 60000 units).
  • the daily combination dosage of serrapeptase for an adult is usually between 1 and 30 mg (2000 and 60000 units), preferably between 2 and 22.5 mg (4000 and
  • the daily combination dosage of bromelain for an adult is usually between 10 and 320 mg (5000 and 160000 units), preferably between 20 and 240 mg (10000 and 120000 units), more preferably between 40 and 200 mg (20000 and 100000 units).
  • the daily combination dosage of tranexamic acid for an adult is usually between 25 and 2000 mg, preferably between 50 and 1500 mg, more preferably between 75 and 750 mg.
  • the at least one second pharmaceutically active compound is selected from the group consisting of crude drugs.
  • the amount of the one or more crude drugs in the oral pharmaceutical dosage form according to the present invention may be varied depending on the . type of the crude drug. It preferably lies in the range from 0.001 to 20 g, and more preferably in the range from 0.002 to 10 g. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called “daily combination dosage") of suitable crude drugs comprised in a composition according to this invention are specified.
  • the daily combination dosage of earthworm and/or scutellaria root for an adult is usually in the range up to 6 g, preferably between 0.2 and 4.5 g, more preferably between 0.4 and 3 g as crude drug substance.
  • the daily combination dosage of cinnamon bark for an adult is usually in the range up to 10 g, preferably between 0.1 and 7.5 g, more preferably between 0.2 and 5 g as crude drug substance.
  • the daily combination dosage of peony root, atractylodes lancea rhizome and/or atractylodes rhizome for an adult is usually in the range up to 10 g, preferably between 0.2 and 7.5 g, more preferably between 0.4 and 5 g as crude drug substance.
  • the daily combination dosage of moutan bark, Japanese valerian, panax rhizome and/or ginseng for ah adult is usually in the range up to 12 g, preferably between 0.2 and 9 g, more preferably between 0.4 and 6 g as crude drug substance.
  • the daily combination dosage of zanthoxylum fruit and/or perilla herb for an adult is usually in the range up to 4 g, preferably between 0.1 and 3 g, more preferably between 0.2 and 2 g as crude drug substance.
  • the daily combination dosage of ginger for an adult is usually in the range up to 6 g, preferably between 0.05 and 4.5 g, more preferably between 0.1 and 3 g as crude drug substance.
  • the daily combination dosage of citrus unshiu peel for an adult is usually in the range up to 10 g, preferably between 0.15 and 7.5 g, more preferably between 0:3 and 5 g as crude drug substance.
  • the daily combination dosage of German chamomile and/or rice for an adult is usually in the range up to 20 g, preferably between 1 and 15 g, more preferably between 2 and 10 g as crude drug substance.
  • the daily combination dosage of apricot kernel for an adult is usually in the range up to 8 g, preferably between 0.3 and 6 g, more preferably between 0.6 and 4 g as crude drug substance.
  • the daily combination dosage of poria sclerotium for an adult is usually in the range up to 10 g, preferably between 0.5 and 7.5 g, more preferably between 1 and 5 g as crude drug substance.
  • the daily combination dosage of cyperus rhizome and/or jujube for an adult is usually in the range up to 8 g, preferably between 0.2 and 6 g, more preferably between 0.4 and 4 g as crude drug substance.
  • the daily combination dosage of fennel, phellodendron bark, zedoary, magnolia bark, schisandra fruit and/or asiasarum root for an adult is usually in the range up to 6 g, preferably between 0.3 and 4.5 g, more preferably between 0.6 and 3 g as crude drug substance.
  • the daily combination dosage of coptis rhizome for an adult is usually in the range up to 6 g, preferably between 0.15 and 4.5 g, more preferably between 0.3 and 3 g as crude drug substance.
  • the daily combination dosage of gentian and/or bear bile for an adult is usually in the range up to 1 g, preferably between 0.05 and 0.75 g, more preferably between 0.1 and 0.5 g as crude drug substance.
  • the daily combination dosage of oriental bezoar for an adult is usually in the range up to 0.04 g, preferably between 0.001 and 0.03 g, more preferably between 0.002 and 0.02 g as crude drug substance.
  • the daily combination dosage of fourleaf ladybell root for an adult is usually in the range up to 10 g, preferably between 0.25 and 7.5 g, more preferably between 0.5 and 5 g as crude drug substance.
  • the daily combination dosage of clove for an adult is usually in the range up to 4 g, preferably between 0.05 and 3 g, more preferably between 0.1 and 2 g as crude drug substance.
  • the daily combination dosage of pueraria root and/or ophiopogon tuber for an adult is usually in the range up to 16 g, preferably between 0.8 and 12 g, more preferably between 1.6 and 8 g as crude drug substance.
  • the daily combination dosage of bupleurum root for an adult is usually in the range up to 14 g, preferably between 0.5 and 10.5 g, more preferably between 1 and 7 g as crude drug substance.
  • the daily combination dosage of pinellia tuber for an adult is usually in the range up to 10 g, preferably between 0.4 and 7.5 g, more, preferably between 0.8 and 5 g as crude drug substance.
  • the preferred dosage ranges of the crude drugs according to the invention are specified above. These dosage ranges apply in case only one crude drug is combined with meloxicam as well as two or more crude drugs, e.g. as a Kampo medicine formulation, are combined with meloxicam. In the following preferred amounts to be given daily to an adult (in the following called “daily combination dosage”) of Kampo medicine formulations comprised in an oral pharmaceutical dosage form according to this invention are specified.
  • the daily combination dosage of kakkon-to for an adult is usually in the range up to 25 g, preferably between 0.5 and 20 g, more preferably between 5 and 12.5 g as crude drug substance.
  • the daily combination dosage of keishi-to for an adult is usually in the range up to 15 g, preferably between 0.3 and 12.5 g, more preferably between 3 and 7.5 g as crude drug substance.
  • the daily combination dosage of kouso-san for an adult is usually in the range up to 11 g, preferably between 0.1 and 9 g, more preferably between 1.2 and 5.5 g as crude drug substance.
  • the daily combination dosage of saiko-keishi-to, sho-saiko-to and sho-seiryu-to for an adult is usually in the range up to 24 g, preferably between 0.4 and 18 g, more preferably between 4.8 and 12 g as crude drug substance.
  • the daily combination dosage of bakumondo-to for an adult is usually in the range up to 30 g, preferably between 0.6 and 18 g, more preferably between 6 and 15 g as crude drug substance.
  • the daily combination dosage of hange-koboku-to for an adult is usually in the range up to 6 g, preferably between 0.3 and 12 g, more preferably between 3.2 and 8 g as crude drug substance.
  • the daily combination dosage of mao-to for an adult is usually in the range up to 13 g, preferably between 0.2 and 10 g, more preferably between 2.6 and 6.5 g as crude drug substance.
  • the oral pharmaceutical dosage form of the invention may be orally given in divided doses, as e.g. 2, 3 or 4 doses per day. However, the oral pharmaceutical dosage form is preferably given orally once a day. Dose adjustment of meloxicam and the crude drug may reflect age, body weight, and. manifesting symptoms.
  • the oral pharmaceutical dosage form described in the present invention comprises tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chewable tablets, troches, effervescent tablets, drops, suspension, fast dissolving tablets, oral fast-dispersing tablets, etc..
  • Any of these formulations may be prepared using regular methods, and, in addition to the aforementioned components, any additives in common use may be used upon preparation of these formulations, if necessary.
  • preparations formed into microparticles such as microcapsules, nanocapsules, microspheres, nanospheres, may also be included in the aforementioned formulations.
  • compositions of the oral pharmaceutical dosage form and the formulation of all ingredients are preferably chosen in view of the desired mechanical, chemical and biological stability, release rate, masking of the taste, visual appearance, etc..
  • the pharmaceutically active substances i.e. meloxicam or a pharmaceutically salt thereof and the second pharmaceutically active agent
  • the pharmaceutically active substances can be dispensed in separate granules, multi-layer granules, multi-layer tablets or dry coated tablets, tablets of separated granules, microcapsules, etc.
  • Coating preparations such as sugarcoated tablets, film coating tablets, coating granule, can be used as well as chewable tablets, oral fast dispersing tablets, matrix tablets, matrix granules, effervescent tablets, dusting powder, solid solutions, etc. These methods can also be combined.
  • the properties of the inventive oral pharmaceutical dosage form such as stability, release, continuance, disintegration, distinglation, dissolution, concealment of taste, improvement in usage etc. can be regulated by the addition of additives known in the art.
  • the oral dosage form is a combination of a first dosage form comprising meloxicam or a pharmaceutically acceptable salt thereof and a second dosage form comprising the at least second pharmaceutically active compound.
  • the first dosage form releases the active ingredients faster than the second dosage form.
  • the first dosage form may further comprise the second pharmaceutically active compound and optionally further active ingredients.
  • the second dosage form may comprise further active ingredients.
  • the second dosage form does not comprise meloxicam.
  • the dosage form is a two layer tablet wherein the first layer comprises meloxicam or a pharmaceutical acceptable salt thereof and optionally a second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients.
  • the second layer comprises the second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients, whereby the second layer has slow release properties compared with the first layer.
  • the dosage form is a capsule comprising two kinds of granules.
  • the first kind of granules comprise meloxicam or a pharmaceutical acceptable salt thereof and optionally a second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug , and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients.
  • the second kind of granules comprise the second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients, whereby the second kind of granules have slow release properties compared with the first kind of granules.
  • formulations may be prepared using regular methods by adding generally available pharmaceutical additives such as excipients, binders, disintegrators, lubricants, coating agents, sugar coating agents, plasticizers, antifoaming agents, polish, foaming agents, antistatic agents, desiccant, surfactant, solubilizer, buffer agents, resolvents, solubilizing agents, solvents, diluents, stabilizers, emulsifying agents, suspension, suspending agents, dispersing agents, isotonizing agents, adsorbents, reducing agents, antioxidant, wetting agents, wet modifier, filler, extender, adhesives, viscous agent, softeners, pH modifiers, antiseptics, preservatives, sweetening agents, corrigent, refrigerative agents, flavoring agents, perfume, fragrance, and coloring matters to the pharmacologically active compounds.
  • additives are described in Japanese Pharmaceutical Excipients Directory 2000 (edited by Japan Pharmaceutical Excipients Council, issued by Yakuji
  • Suitable pharmaceutical additives, carriers and excipients are lactose, sucrose, glucose, mannitol, xylitol, corn starch, potato starch, wheat starch, rice starch, tapioca starch, sodium carboxymethyl starch, microcrystalline cellulose, ethylcellulose, hydroxypropylmethylcellulose, low substituted hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium, carmellose, carmellose potassium, carmellose calcium, carmellose sodium, polyvinylpyrrolidone, propyleneglycol, polyethyleneglycol, glycerol, vegetable oils, waxes, crospovidone, agar, light anhydrous silicic acid, magnesium stearate, talc, titanium oxide, acacia, sodium alginate, ethanol, purified water and etc...
  • preparations are preferably manufactured by adding pharmaceutical additives to the pharmacologically active compounds.
  • compositions and dosage forms according to this invention are advantageously usefull as analgesics, antipyretics and/or antiinflammatory agents.
  • the invention relates to the use of the pharmaceutical composition and of the oral pharmaceutical dosage form, both as described hereinbefore, for the treatment and alleviation of an inflammatory disease, symptoms of an inflammatory disease such as headache, toothache, ache after tooth extraction, menstrual pain, sore throat, joint pain, muscle pain, otalgia, arthralgia,. neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, traumatic pain, earache, chill, exothermic reaction and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.
  • an inflammatory disease such as headache, toothache, ache after tooth extraction, menstrual pain, sore throat, joint pain, muscle pain, otalgia, arthralgia,. neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture,
  • this invention relates to the use of the pharmaceutical composition and of the oral pharmaceutical dosage form, both as described hereinbefore, for the treatment and alleviation of various symptoms of common cold, for example such as fever, sore throat, chills, headache, joint, pain muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
  • compositions and dosage forms of the invention are effective for the treatment and alleviation of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.
  • this invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for the manufacture of an oral pharmaceutical dosage form according to this invention.
  • the invention also relates to the use of a pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs for the manufacture of an oral pharmaceutical dosage form according to this invention.
  • this- invention further relates to a method of treating or alleviating of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain, in a patient in need of such treatment, which comprises orally administering to the patient a pharmaceutical composition according to this invention.
  • this invention also relates to a method of treating or alleviating of various symptoms of common cold, for example such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm in a patient in need of such treatment, which comprises orally administering to the patient a pharmaceutical composition according to this invention.
  • various symptoms of common cold for example such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
  • the patient to be treated according to this invention is a mammal, preferably a human.
  • the preferred daily ' dose orally administered to the patient according to this invention is in the range of 1 to 30 mg meloxicam, more preferably 2.5 to 15 mg meloxicam, and a) in case the second pharmaceutically active compound is one or more vitamins, an amount of 0.1 to 2000 mg, more preferably 0.1 to 500 mg, of the one or more vitamins; b) in case the second pharmaceutically active compound is one or more antiphlogistic agents, an amount of 1 to 2000 mg, more preferably 3 to 750 mg, of the one or more antiphlogistic agents; c) in case the second pharmaceutically active compound is one or more crude drugs, an amount of of 0.001 to 20 g, more preferably 0.002 to 10 g, of the one or more crude drugs.
  • the amount of the dosage form to be taken by a patient per day i.e. the number of tablets, capsules, caplets, troches, etc., or the amount of granules, syrup, solution, suspension, etc., e.g. measured in grams or milliliters, is such that the above specified preferred daily dose is achieved.
  • Meloxicam or a pharmaceutically acceptable salt thereof and the at least one pharmaceutically active compound are preferably combined in a single oral dosage form as described above. Both, meloxicam or a salt thereof and the at least one pharmaceutically active compound may also be simultaneously administered in two separate oral dosage forms, one containing meloxicam or a salt thereof and the other containing the second pharmaceutically active compoundvitamin.
  • compositions and dosage forms of the present invention are explained by the following examples which however do not limit the scope of the present invention.
  • the examples 1.1 to 1.6 illustrate the first embodiment of the present invention
  • the examples 2.1 to 2.6 illustrate the second embodiment of the present invention
  • the examples 3.1 to 3.6 illustrate the third embodiment of the present invention.
  • Example 1.1 Tablet The following ingredients are homogeneously mixed. The resulted mixed particles are compressed with a mold to prepare 250 mg-tablets.
  • Meloxicam 45 g Bisbentiamine 60 g Riboflavin 36 g Hesperidin 120 g Lactose 603 g Microcrystalline cellulose 606 g Light anhydrous silicic acid 15 g Magnesium stearate 9 g Talc 6 g
  • the following ingredients are homogeneously mixed.
  • the resulted mixed particles are divided into 750 mg per portion.
  • layer A and layer B are prepared by a regular method to provide mixed particles, and the particles are compressed to form 320 mg of two layer tablet (layer A 100 mg, layer B 220 mg).
  • Layer A Meloxicam 15 g Thiamine hydrochloride 20 g Riboflavin sodium phosphate 4 g Allylisopropylacetylurea 120 g Anhydrous caffeine 160 g Lactose 135 g Microcrystalline cellulose 134 g Light anhydrous silicic acid .
  • the following ingredients are prepared as granules by a regular method to prepare mixed particles.
  • the granules are packed in amounts of 1000 mg.per pack.
  • the following ingredients are prepared by a regular method to provide mixed particles, and the particles are compressed to form 175 mg-tablets.
  • the tablets are transferred into a coating pan, and are coated using the equal volume mixture of ethyl alcohol contained 5% weight/volume of hydroxypropylmethylcellulose and purified water to increase in weight/volume by 5 mg per one tablet.
  • film-coating tablets are prepared.
  • the following ingredients are prepared as granules by regular methods, and filled into capsules, whereby the amount per capsule is 150 mg.
  • Meloxicam 60 g Thiamine nitrate 8 g Riboflavin 16 g Ascorbic acid 400 g Hesperidin 144 g Allylisopropylacetylurea 480 g Anhydrous caffeine 240 g Mannitol 296 g Microcrystalline cellulose 756 g
  • the following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 300 mg (layer A 100 mg, layer B 200 mg) each.
  • Layer A Meloxicam 15 g Tranexamic acid 280 g Anhydrous caffeine 160 g Lactose 95 g Microcrystalline cellulose 230 g Sodium lauryl sulfate 6 g Light anhydrous silicic acid 6 g Talc 4 g Magnesium stearate 4 g
  • Layer B Tranexamic acid 560 g Anhydrous caffeine 320 g Lactose 84 g Fumaric acid 100 g Succinic acid 100 g Hydroxypropylmethylcellulose 2208 100 g Hydrogenated oil 160 g Stearic acid 80 g Glycerol esters of fatty acids 80 g Magnesium stearate 16 g
  • the following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 310 mg (layer A 110 mg, layer B 200 mg) each.
  • Layer A Meloxicam 45 g Semi-alkaline proteinase 60.
  • the following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1300 mg per one pack of granules.
  • Meloxicam 37.5 g Bromelain 500.0 g Clemastine fumarate 6.7 g Dihydrocodeine phosphate 40.0 g dl-Methylephedrine hydrochloride 100.0 g Bromhexine hydrochloride 20.0 g Anhydrous caffeine 250.0 g
  • Fast release granules Meloxicam 60.0 g Triprolidine hydrochloride 9.6 g Tipepidine hibenzate 160.0 g dl-Methylephedrine hydrochloride 160.0 g Anhydrous caffeine 240.0 g Microcrystalline cellulose 810.4 g Delayed release granules: Serrapeptase 40.0 g Microcrystalline cellulose 160.0 g Hydroxypropylmethylcellulose phthalate (coating layer) 36.0 g Glycerol esters of fatty acids (coating layer) 3.2 g Talc (coating layer) 0.8 g Slow release granules: Triprolidine hydrochloride 19.2 g Tipepidine.
  • Fast release granules Meloxicam 60.0 g Isothipendyl hydrochloride 24.0 g Guaifenesin 666.4 g dl-Methylephedrine hydrochloride . 160.0 g Anhydrous caffeine 200.0 g Microcrystalline cellulose 729.6 g Delayed release granules: Semi-alkaline proteinase 80.0 g Microcrystalline cellulose 120.0 g Methacrylic acid copolymer LD (coating layer) 28.8 g Macrogol 6000 (coating layer) 3.2 g Talc (coating layer) 8.0 g Slow release granules: Isothipendyl hydrochloride 32.0 g Guaifenesin 1333.6 g dl-Methylephedrine hydrochloride 320.0 g Anhydrous caffeine 400.0 g Fumaric acid 400.0 g Microcrystalline cellulose 762.4 g Methacrylic acid copolymer S (coating layer
  • the following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1500 mg per one pack of granules.
  • the following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1400 mg per one pack of granules.
  • Peony root extract 200 extract of 2 kg Peony root
  • Glycyrrhiza extract 400 extract of 2 kg Glycyrrhiza
  • Calcium carboxymethylcellulose 240 g Mannitol 1400 g Corn starch 220 g Light anhydrous silicic acid 42 g Aspartame 10 g Acesulfame potassium 10 g Fragrant materials 3 g
  • the following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1500 mg per one pack of granules.
  • the following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 400 mg (layer A 200 mg, layer B 200 mg) each.
  • Layer A Meloxicam 15 g Japanese valerian extract 320 g (extract of 1.2 kg Japanese valerian) Allylisopropylacetylurea 120 g Anhydrous caffeine 120 g Lactose 161 g Microcrystalline cellulose 440 g Sodium lauryl sulfate 6 g Light anhydrous silicic acid 6 g Talc 8 g Magnesium stearate 4 g
  • Layer B Allylisopropylacetylurea 240 g Anhydrous caffeine 240 g Lactose 68 g Fumaric acid 120 g Hydroxypropylmethylcellulose 2208 180 g Hydrogenated oil 120 g Stearic acid 120 g Glycerol, esters of fatty acids 120 g Magnesium stearate
  • the following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablet at 270 mg (layer A 130mg, layer B 140mg) each.
  • Layer A Meloxicam ' 15 g Ginseng extract 200 g (extract of 2.9 kg Ginseng) Gentian extract 40 g (extract of 0.4 kg Gentian) Isothipendyl hydrochloride 5 g Ambroxol hydrochloride 30 g Dihydrocodeine phosphate 16 g dl-Methylephedrine hydrochloride 40 g Anhydrous caffeine 50 g Lactose .
  • Example 3.6 Capsules The following ingredients are prepared as fast release granules and slow release granules through regular methods, and capsule-filled to give an amount of 300 mg
  • Fast release granules Meloxicam 60 g Powdered oriental bezoar 24 g Epinastine hydrochloride 80 g Ambroxol hydrochloride 120 g Dihydrocodeine phosphate 64 g f/ " -MethyIephedrine hydrochloride 160 g Noscapine 128 g Anhydrous caffeine 200 g Lysozyme hydrochloride 240 g Bisibutiamine 96 g Riboflavin 48 g Corn starch 160 g Hydroxypropylcellulose 40 g Microcrystalline cellulose 500 g Slow release granules: Ambroxol hydrochloride 240 g Dihydrocodeine phosphate 128 g dl-Methylephedrine hydrochloride 320 g Noscapine 256 g Anhydrous caffeine 400 g Fumaric acid 336 g Corn starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising meloxicam or a pharmaceutically acceptable salt thereof and a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs.

Description

Compositions comprising meloxicam
This invention relates to a pharmaceutical composition comprising meloxicam or a pharmaceutically acceptable salt thereof and at least a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs. Furthermore this invention relates to an oral pharmaceutical dosage form comprising such a composition. A further objective of this invention is related to the use of the composition and the oral pharmaceutical dosage form. In addition this invention relates to the use of meloxicam and at least a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs for the manufacture of such an oral pharmaceutical dosage form. Furthermore, this inventions relates to a method of treating or alleviating of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as fever, pyrexia, arthralgia, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
Background of the invention
Many NSAIDs are COX inhibitors, which nonspecifically inhibit cyclooxygenase (COX), a rate-limiting enzyme for biosynthesis of prostaglandin (PG) from arachidonic acid. Inhibition of COX contributes to anti-inflammatory, analgesic and antipyretic effects by inhibiting production of PGE2, on the other hand, it also causes adverse drug reactions such as digestive disorders and renal disorders. Incidentally, COX includes two types of isoforms, i.e. COX-1 and COX-2. COX-1 is constitutively (a certain amount of protein is developed regardless of proliferation or environmental changes) developed in most of the organs such as stomach and kidneys. And it has become evident that COX-2 is induced by various inflammatory mediators or endotoxin in local inflammatory areas. Meloxicam is a known selective COX-2 inhibitor. Oral administration of a selective COX-2 inhibitor still may, however, cause some side effects in the digestive system such as stomach indisposition and stomachache. Thus, oral pharmaceutical compositions with strengthened efficacy and superior safety by increasing anti-inflammatory, analgesic and antipyretic effects, while alleviating side effects such as gastrointestinal disorders are desired.
The international patent applications WO 2005/016243 describes a composition of a COX-2 inhibitor and an antioxidant agent for the treatment of central nervous system disorders.
A combination of an inhibitor of nitric oxide synthase for treatment of inflammation and inflammatory diseases and a COX-2 inhibitor for treatment of inflammation-related diseases is disclosed in the specification of International Publication WO 99/18960.
A combination of a COX-2 inhibitor and a leukotriene B4 receptor antagonist as effective for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication WO 96/41645.
A combination of a COX-2 inhibitor and a 5-lipoxygenase inhibitor as effective for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication W096/41626.
A composition comprising a COX-2 inhibitor and a leukotriene A4 hydroxylase inhibitor for treatment of inflammation and inflammation-related diseases is disclosed in the specification of International Publication WO 96/41625.
A pharmaceutical composition comprising a COX-2 inhibitor and opioid analgesics as a method to increase efficacy of meloxicam is disclosed in the specification of the international publication WO 99/13799. A pharmaceutical composition comprising morphine and meloxicam in the ratio of 1 :10 is disclosed therein. Such a composition is, however, unfavorable for safety reasons since opioid may cause undesirable side effects. Objective of the present invention
The aim of the present invention is to further improve the safety profile of meloxicam with respect to possible side effects and to provide a pharmaceutical composition and an oral pharmaceutical dosage form comprising meloxicam and having improved anti-inflammatory, analgesic and antipyretic effects.
The present invention aims to provide highly safe oral pharmaceutical compositions comprising meloxicam with more improved anti-inflammatory, analgesic and antipyretic effects.
A further objective of this invention is to provide more effective pharmaceutical compositions for the treatment of a cold with improved efficacy and safety.
A further aim of this invention is to provide a method of treating or alleviating inflammatory diseases, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, fever, and the like.
A further aim of this invention is to provide a method of treating or alleviating of a cold, including various symptoms thereof, such as sore throat, fever, chills, headache, runny nose, stuffy nose, sneezing, cough, phlegm, joint pain, muscular pain and the like.
Description of the invention
This invention relates to new pharmaceutical compositions comprising meloxicam or a pharmaceutically acceptable salt thereof and and a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs. Preferably meloxicam or the salt thereof is present in an effective amount allowing itself to exert anti-inflammatory, analgesic and antipyretic effects. An advantage of the present invention is that the composition of the invention allows a reinforcement of the therapeutic effects such as analgesic, anti-inflammatory and antipyretic effects without the need to increase. the dose of meloxicam. It is possible to provide pharmaceutical compositions as oral pharmaceutical dosage forms with improved efficacy and safety. Possible side effects of common NSAIDs, as e.g. gastrointestinal disorders, are avoided or alleviated by using meloxicam. Thus the composition of the present invention is especially suitable for the treatment or alleviation of inflammatory disease and to alleviate its symptoms such as headache, toothache, menstrual pain, sore throat, joint pain, muscle pain, neuralgia, lumbago, stiff shoulder, tooth extraction pain, contusion pain, earache, fracture pain, sprain pain, traumatic pain, chill and/or fever. And the composition of the present invention is especially suitable for the treatment or alleviation of common cold and to alleviate its symptoms such as fever, sore throat, chills, headache, joint pain muscular pain and/or phlegm. The improved safety profile enables the use of such compositions in non-prescription drugs.
Meloxicam is a known selective COX-2 inhibitor which belongs to the acid enolcarboxamide (oxicam) type of non-steroidal anti-inflammatory drugs (NSAIDs). The compound (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H1 ,2-benzothiazine- 3-carboxamide 1 ,1 -dioxide) is described in EP 0 002 482 B1 and US 4,233,299.
The invention may employ either meloxicam itself or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt of meloxicam includes sodium salt, potassium salt, ammonium salt, meglumine salt, tris salt, and salts of meloxicam with a basic amino acid as examples. Various salts of meloxicam are described in EP 0 002482 B1 , US 4,233,299 and WO 99/49867.
According to a first embodiment of this invention the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins.
In addition to meloxicam and vitamin mentioned above, the compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent and/or an expectorant.
By using an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
The addition of a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam.
By using a sedative as a further ingredient a reinforcement of analgesic, anti-inflammatory and antipyresis therapeutic effect is obtainable. By using an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
By using an expectorant an additional alleviation of symptoms of common cold, like e;g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
>
Therefore a pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one antacid. This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antitussive agent, one or more, preferably one expectorant and/or one or more, preferably one sedative.
A further pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one central nervous system stimulant. This composition may additionally comprise one or more, preferably one antacid, one or more, preferably one antitussive agent, one or more, preferably one expectorant and/or one or more, preferably one sedative.
Again a further pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one antitussive agent. This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one expectorant and/or one or more, preferably one sedative.
Again a further pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one expectorant. This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one or two antitussive agents and/or one or more, preferably one sedative.
Again a further pharmaceutical composition according to this invention may comprise meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins according to this invention and one or more, preferably one sedative. This composition may additionally comprise one or more, preferably one central nervous system stimulant, one or more, preferably one antacid, one or more, preferably one expectorant and/or one or more, preferably one or two antitussive agents.
According to a second embodiment of this invention the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more antiphlogistic drugs.
In addition to meloxicam and one or more antiphlogistic agents mentioned above, the compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin and/or an anti-H1-histamine. Preferably for antipyretic analgesics, a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant and/or a vitamin.
Preferably for cold remedies, a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin and/or an anti-H1-histamine.
By using an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
By using a sedative as a further ingredient a reinforcement of therapeutic effects of analgesic, anti-inflammatory and antipyresis, can be obtained.
The addition of a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam.
By using an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
By using an expectorant an additional alleviation of symptoms of common cold, like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
By using a vitamins as further ingredients a reinforcement of therapeutic effects such as analgesic, anti-inflammatory and antipyretic effects is obtainable.
By using an anti-H1-histamine as a further ingredient an alleviation of symptoms of common cold such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose and/or sneezing is obtainable.
According to a third embodiment of this invention the pharmaceutical composition comprises meloxicam or a pharmaceutically acceptable salt thereof and one or more crude drugs.
In addition to meloxicam and one or more crude drug mentioned above, the compositions of the present invention may also include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-H1-histamine and/or an antiphlogistic agent.
Preferably for antipyretic analgesics, a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a sedative, a central nervous system stimulant, a vitamin and/or an antiphlogistic agent.
Preferably for cold remedies, a pharmaceutical composition according to this invention may include other pharmacologically active substances such as an antacid, a central nervous system stimulant, an antitussive agent, an expectorant, a vitamin, an anti-Hi -histamine and/or an antiphlogistic agent.
By using an antacid as a further ingredient an improvement of the bioavailability and/or a decrease of the possibility of side effects in the digestive system may be obtained.
By using a sedative as a further ingredient a reinforcement of therapeutic effects of analgesic, anti-inflammatory and antipyresis, can be obtained.
The addition of a central nervous system stimulant may reinforce therapeutic effects such as analgesic, anti-inflammatory and antipyresis without the necessity of increasing the dose of meloxicam. By using an antitussive agent as a further ingredient an additional alleviation of symptoms, like e.g. cough and sneezing, can be obtained.
By using an expectorant an additional alleviation of symptoms of common cold, like e.g. fever, sore throat, chill, headache, joint pain, muscular pain, and/or sputum, can be obtained.
By using a vitamin and/or an antiphlogistic as further ingredients a reinforcement of therapeutic effects such as analgesic, anti-inflammatory and antipyretic effects is obtainable.
By using an anti-H1-histamine as a further ingredient an alleviation of symptoms of common cold such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose and/or sneezing is obtainable.
In the following the preferred active ingredients in the compositions according to this invention are described in more detail:
The compositions according to this invention may comprise one or more vitamins as a second or further active ingredient in addition to meloxicam.
In the foregoing and in the following the term "vitamin" includes vitamins as such, vitamin-like substances and salts and derivatives of vitamins and of vitamin-like substances.
The compositions in the present invention may comprise one, two, three or more vitamins, which preferably are selected from the group consisting of vitamin B1 , vitamin B2, vitamin C and/or hesperidin, including salts, in particular pharmaceutically acceptable salts, and derivatives thereof.
Vitamin B1 used in the present invention is preferably selected from the group consisting of thiamine, thiamine hydrochloride, thiamine nitrate, thiamine disulfide nitrate, thiamine disulfide, thiamine dicetylsulfate salt, dicethiamine hydrochloride, fursultiamine hydrochloride, fursultiamine, octotia ine, cycotiamine, bisibutiamine, bisbentiamine, prosultiamine, benfotiamine, cocarboxylase, dibenzoylthiamaine, etc.
Vitamin B2 used in the present invention is preferably selected from the group consisting of riboflavin, riboflavin butyrate, riboflavin sodium phosphate, flavin adenine dinucleotide, etc.
Vitamin C used in the present invention is preferably selected from the group consisting of ascorbic acid, sodium ascorbate, calcium ascorbate, etc.
Hesperidin used in the present invention is preferably selected from the group consisting of hesperidin, alpha G hesperidin, etc.
The compositions according to this invention may comprise one or more antiphlogistic agents as a second or further active ingredient in addition to meloxicam.
The one or more antiphlogistic agents used in the present invention is preferably selected from the group consisting of semi-alkaline proteinase, serrapeptase, bromelain and tranexamic acid. One of these antiphlogistic agents can be used in combination with meloxicam or a combination of two or more of these antiphlogistic agents can be used together with meloxicam.
The compositions according to this invention may comprise one or more crude drugs as a second active ingredient in addition to meloxicam.
The one or more crude drug used in the present invention is preferably selected from the group consisting of earthworm (Lumbricus), cinnamon bark (Cinnamomi cortex), peony root (Paeoniae radix), moutan bark (Moutan cortex), Japanese valerian (Velerianae radix) , zanthoxylum fruit (Zanthoxylifi'uctus), ginger (Zingϊberis rhizoma), citrus unshiu peel (Aurantii nobilis pericarpium), fennel (Foeniculi fructus), phellodendron bark (Phellodendri cortex), coptis rhizome (Coptidis rhizoma), zedoary (Zedoariae rhizoma), German chamomile (Chamomillaflos), gentian (Gentianae radix), oriental bezoar (Bezoar bovis), bear bile (Fel ursi), fourleaf ladybell root (Adenophorae radix), atractylodes lancea rhizome (Atractylodis lanceae rhizoma), clove {Caryophylli flos), atractylodes rhizome (Atractylodis rhizoma), panax rhizome (Panacis japonici rhizoma), ginseng (Ginseng radix), scutellaria root (Scutellariae radix), pueraria root (Puerariae radix), apricot kernel (Armeniacae semen), cyperus rhizome (Cyperi rhizoma), rice (Oryzae semen), magnolia bark (Magnoliae cortex), schisandra fruit (Schisandrae fructus), bupleurum root (Bupleuri radix), asiasarum root (Asiasari radix), perilla herb (Perillae herba), jujube (Zizyphi fructus), ophiopogon tuber (Ophiopogonis tuber), pinellia tuber (Pinelliae tuber)and poria sclerotium (Poriα). One of these crude drugs can be used in coombination with meloxicam or a combination of two or more of these crude drugs can be used together with meloxicam.
Preferably the one or more crude drugs are selected from the group consisting of earthworm, cinnamon bark, peony root, Japanese valerian, ginger, fennel, phellodendron bark, coptis rhizome, German chamomile, gentian, oriental bezoar, ginseng, scutellaria root, pueraria root, apricot kernel, jujube.
These crude drug can be in the form of a dried powder, an extract, a fluidextract, a tincture, an oil or other kind of preparations known to the one skilled in the art.
According to a further embodiment of this invention the crude drug is a formulation according to the Kampo medicine. Examples of Kampo medicine formulations are described in 2004-5 Drug in Japan : OTC-Drugs (edited by Japan Pharmaceutical Information Center, issued by Yakuji Nippo, Ltd.). Preferred examples of Kampo medicine formulations are kakkon-to, keishi-to, kouso-san, saiko-keishi-to, sho-saiko-to, sho-seiryu-to, bakumondo-to, hange-koboku-to and mao-to. In the following the preferred contents of the Kampo medicine formulations as mentioned above is given. Kakkon-to is an extract of the crude drugs pueraria root, glycyrrhiza, cinnamon bark, peony root, ginger, ephedra herb and jujube, preferably of the approximate ratios 8 : 2 : 3 : 3 : 1 : 4 : 4 by weight. Keishi-to is an extract of the crude drugs glycyrrhiza, "cinnamon bark, peony root, ginger and jujube, preferably of the approximate ratios 2 : 4 : 4 : 1 : 4 by weight. Kouso-san is an extract or a powder of the crude drugs glycyrrhiza, ginger, citrus unshiu peel, cyperus rhizome and perilla herb, preferably of the approximate ratios 1 : 1 : 3 : 4 : 2 by weight. Saiko-keishi-to is an extract of the crude drugs glycyrrhiza, cinnamon bark, peony root, ginger, ginseng, scutellaria root, bupleurum root, jujube and pinellia tuber, preferably of the approximate ratios 2 : 3 : 3 : 1 : 2 : 2 : 5 : 2 : 4 by weight. Sho-saiko-to is an extract of the crude drugs glycyrrhiza, ginger, ginseng, scutellaria root, bupleurum root, jujube and pinellia tuber, preferably of the approximate ratios 2 : 1 : 3 : 3 : 7 : 3 : 5 by weight. Sho-seiryu-to is an extract of the crude drugs glycyrrhiza, cinnamon bark, peony root, ginger, ephedra herb, schisandra fruit, asiasarum root and pinellia tuber, preferably of the approximate ratios 2 : 3 : 3 : 2 : 3 : 3 : 3 : 5 by weight. Bakumondo-to is an extract of the crude drugs glycyrrhiza, ginseng, rice, jujube, ophiopogon tuber and pinellia tuber, preferably of the approximate ratios 2 : 2 : 10 : ' 3 : 8 : 5 by weight. Hange-koboku-to is an extract of the crude drugs ginger, magnolia bark, perilla herb, pinellia tuber and poria sclerotium, preferably of the approximate ratios 1 : 3 :
2 : 5 : 5 by weight. Mao-to is ah extract of the crude drugs glycyrrhiza, cinnamon bark, ephedra herb and apricot kernel, preferably of the approximate ratios 2 : 3 : 4 : 4 by weight.
In the following the preferred further active ingredients in the compositions according to this invention are described in more detail:
Examples of suitable antacids are aminoacetic acid, synthetic aluminum silicate, hydrotalcite, magnesium oxide, dihydroxy aluminum aminoacetate, aluminum hydroxide gel, dried aluminum hydroxide -gel, aluminum hydroxide-sodium bicarbonate co-precipitate, magnesium carbonate, magnesium aluminometasilicate, magnesium hydroxide, sodium hydrogencarbonate and calcium hydrogenphosphate and the like.
Examples of suitable sedatives are allylisopropylacetylurea and bromvalerylurea and the like.
Examples of suitable central nervous system stimulants are caffeine (3,7-dihydro-1 ,3,7-trimethyl-1 H-purine-2,6-dione monohydrate), anhydrous caffeine (3,7-dihydro-1 ,3,7-thmethyl-1 H-purine-2,6-dione) and a salt complex of caffeine and sodium benzoate (caffeine and sodium benzoate) and the like. Also combinations of two or more central nervous system stimulants may be used.
Examples of suitable antitussive agents are tipepidine citrate, tipepidine hibenzate, dextromethorphan hydrobromide, codeine phosphate, dihydrocodeine phosphate, noscapine hydrochloride, noscapine, dl-methyiephedrine hydrochloride, dimemorfan phosphate, ephedra herb, nandina fruit and the like. More preferably the one or more antitussive agents are selected from the group consisting of tipepidine citrate, dextromethorphan hydrobromide, dihydrocodeine phosphate, hoscapine hydrochloride, noscapine, and dl-methylephedrine hydrochloride. These antitussive agents can be used solely or mixed with more than two kinds.
Examples of suitable expectorants are potassium guaiacolsulfonate, guaifenesin, bromhexine hydrochloride, ambroxol hydrochloride, L-carbocisteine, ethyl L-cysteine hydrochloride, fudosteine, platycodon root, glycyrrhiza, cherry bark, polygala root, plantago seed, plantago herb, lycoris bulb, senega, fritillary bulb and the like. More preferably the one or more expectorants are selected from the group consisting of guaifenesin, bromhexine hydrochloride, ambroxol hydrochloride, L-carbocisteine and fudosteine.
Examples of preferred anti-H1-histamines are diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tannate, diphenylpyraline hydrochloride, diphenylpyraline teoclate, clemastine fumarate, triprolidine hydrochloride, promethazine hydrochloride, promethazine methylenedisalicylate, alimemazine tartrate, isothipendyl hydrochloride, iproheptine hydrochloride, difeterol hydrochloride, difeterol phosphate, tripeiennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, mebhydroline napadisylate, mequitazine, ketotifen fumarate, epinastine hydrochloride, chlorpheniramine maleate, carbinoxamine maleate and the like.
According to a preferred embodiment, the pharmaceutical composition according to this invention further comprises at least one pharmaceutically acceptable carrier and/or excipient. Suitable carriers and excipients are known to the one skilled in the art and are described for example in Japanese Pharmaceutical Excipients Directory 2000 (edited by Japan Pharmaceutical Excipients Council, issued by Yakuji Nippo, Ltd.). Examples of suitable carriers and/or excipients are lactose, sucrose, glucose, mannitol, xylitol, corn starch, potato starch, wheat starch, rice starch, tapioca starch, sodium carboxymethyl starch, microcrystalline cellulose, ethylcellulose, hydroxypropylmethylcellulose, low substituted hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium, carmellose, carmellose potassium, carmellose calcium, carmellose sodium, polyvinylpyrrolidone, propyleneglycol, polyethyleneglycol, glycerol, vegetable oils, waxes, crospovidone, agar, light anhydrous silicic acid, magnesium stearate, talc, titanium oxide, acacia, sodium alginate, ethanol and purified water.
In addition this invention relates to a pharmaceutical dosage form which comprises a pharmaceutical composition according to this invention.
The amount of meloxicam or of a salt thereof used for the oral pharmaceutical dosage form described in the invention is preferably in the range from 1 to 30 mg, more preferably in the range from 2.5 to 15 mg, and most preferably in the range from 5 to 10 mg. These amounts correspond to the preferred dosage ranges with respect to an adult and once daily given dose.
According to the first embodiment of this invention the at least one second pharmaceutically active compound is selected from the group consisting of vitamins. Although the amount of the one or more vitamins in the oral pharmaceutical dosage form according to the present invention may be varied depending on the type of the vitamin. It preferably lies in the range from 0.1 to 2000 mg, and more preferably . in the range from 0.1 to 500 mg. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called "daily combination dosage") of suitable vitamins comprised in a composition according to this invention are specified.
The daily combination dosage of vitamin B1 for an adult is usually about 0.1 to 100 mg, preferably 0.5 to 50 mg, and more preferably 1 to 25 mg.
The daily combination dosage of vitamin B2 for an adult is usually about 0.1 to 45 mg per day, preferably 1 to 30 mg, and more preferably 2 to 12 mg.
The daily combination dosage of vitamin C for an adult is usually about 5 to 2000 mg per day, preferably 25 to 1000 mg, and more preferably 50 to 500 mg.
The daily combination dosage of hesperidin for an adult is usually about 1 to 270 mg per day, preferably 9 to 180 mg, and more preferably 18 to 90 mg.
According to the second embodiment of this invention the at least one second pharmaceutically active compound is selected from the group consisting of antiphlogistic agents. Although the amount of the one or more antiphlogistic agents in the oral pharmaceutical dosage form according to the present invention may be varied depending on the type of the antiphlogistic agent. It preferably lies in the range from 1 to 2000 mg, and more preferably in the range from 3 to 750 mg. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called "daily combination dosage") of suitable antiphlogistic agents comprised in a composition according to this invention are specified.
The daily combination dosage of semi-alkaline proteinase for an adult is usually between 2 and 60 mg (4000 and 120000 units), preferably between 4 and 45 mg (8000 and 90000 units), more preferably between 6 and 30 mg (12000 units and 60000 units).
The daily combination dosage of serrapeptase for an adult is usually between 1 and 30 mg (2000 and 60000 units), preferably between 2 and 22.5 mg (4000 and
450000 units), more preferably between 3 and 15 mg (6000 and 30000 units).
The daily combination dosage of bromelain for an adult is usually between 10 and 320 mg (5000 and 160000 units), preferably between 20 and 240 mg (10000 and 120000 units), more preferably between 40 and 200 mg (20000 and 100000 units).
Detailed specifications of preferred semi-alkaline proteinase, serrapeptase and bromelain are described in Japanese Pharmaceutical Codex 2002 (edited by Society of Japanese Pharmacopoeia, issued by Jiho, inc.).
The daily combination dosage of tranexamic acid for an adult is usually between 25 and 2000 mg, preferably between 50 and 1500 mg, more preferably between 75 and 750 mg.
According to the third embodiment of this invention the at least one second pharmaceutically active compound is selected from the group consisting of crude drugs. Although the amount of the one or more crude drugs in the oral pharmaceutical dosage form according to the present invention may be varied depending on the. type of the crude drug. It preferably lies in the range from 0.001 to 20 g, and more preferably in the range from 0.002 to 10 g. These amounts correspond to the preferred dose given daily to an adult. In the following preferred amounts to be given daily to an adult (in the following called "daily combination dosage") of suitable crude drugs comprised in a composition according to this invention are specified.
The daily combination dosage of earthworm and/or scutellaria root for an adult is usually in the range up to 6 g, preferably between 0.2 and 4.5 g, more preferably between 0.4 and 3 g as crude drug substance.
The daily combination dosage of cinnamon bark for an adult is usually in the range up to 10 g, preferably between 0.1 and 7.5 g, more preferably between 0.2 and 5 g as crude drug substance. The daily combination dosage of peony root, atractylodes lancea rhizome and/or atractylodes rhizome for an adult is usually in the range up to 10 g, preferably between 0.2 and 7.5 g, more preferably between 0.4 and 5 g as crude drug substance.
The daily combination dosage of moutan bark, Japanese valerian, panax rhizome and/or ginseng for ah adult is usually in the range up to 12 g, preferably between 0.2 and 9 g, more preferably between 0.4 and 6 g as crude drug substance.
The daily combination dosage of zanthoxylum fruit and/or perilla herb for an adult is usually in the range up to 4 g, preferably between 0.1 and 3 g, more preferably between 0.2 and 2 g as crude drug substance.
The daily combination dosage of ginger for an adult is usually in the range up to 6 g, preferably between 0.05 and 4.5 g, more preferably between 0.1 and 3 g as crude drug substance.
The daily combination dosage of citrus unshiu peel for an adult is usually in the range up to 10 g, preferably between 0.15 and 7.5 g, more preferably between 0:3 and 5 g as crude drug substance.
The daily combination dosage of German chamomile and/or rice for an adult is usually in the range up to 20 g, preferably between 1 and 15 g, more preferably between 2 and 10 g as crude drug substance.
The daily combination dosage of apricot kernel for an adult is usually in the range up to 8 g, preferably between 0.3 and 6 g, more preferably between 0.6 and 4 g as crude drug substance.
The daily combination dosage of poria sclerotium for an adult is usually in the range up to 10 g, preferably between 0.5 and 7.5 g, more preferably between 1 and 5 g as crude drug substance. The daily combination dosage of cyperus rhizome and/or jujube for an adult is usually in the range up to 8 g, preferably between 0.2 and 6 g, more preferably between 0.4 and 4 g as crude drug substance. > The daily combination dosage of fennel, phellodendron bark, zedoary, magnolia bark, schisandra fruit and/or asiasarum root for an adult is usually in the range up to 6 g, preferably between 0.3 and 4.5 g, more preferably between 0.6 and 3 g as crude drug substance.
The daily combination dosage of coptis rhizome for an adult is usually in the range up to 6 g, preferably between 0.15 and 4.5 g, more preferably between 0.3 and 3 g as crude drug substance. The daily combination dosage of gentian and/or bear bile for an adult is usually in the range up to 1 g, preferably between 0.05 and 0.75 g, more preferably between 0.1 and 0.5 g as crude drug substance.
The daily combination dosage of oriental bezoar for an adult is usually in the range up to 0.04 g, preferably between 0.001 and 0.03 g, more preferably between 0.002 and 0.02 g as crude drug substance.
The daily combination dosage of fourleaf ladybell root for an adult is usually in the range up to 10 g, preferably between 0.25 and 7.5 g, more preferably between 0.5 and 5 g as crude drug substance.
The daily combination dosage of clove for an adult is usually in the range up to 4 g, preferably between 0.05 and 3 g, more preferably between 0.1 and 2 g as crude drug substance.
The daily combination dosage of pueraria root and/or ophiopogon tuber for an adult is usually in the range up to 16 g, preferably between 0.8 and 12 g, more preferably between 1.6 and 8 g as crude drug substance. The daily combination dosage of bupleurum root for an adult is usually in the range up to 14 g, preferably between 0.5 and 10.5 g, more preferably between 1 and 7 g as crude drug substance.
The daily combination dosage of pinellia tuber for an adult is usually in the range up to 10 g, preferably between 0.4 and 7.5 g, more, preferably between 0.8 and 5 g as crude drug substance.
The preferred dosage ranges of the crude drugs according to the invention are specified above. These dosage ranges apply in case only one crude drug is combined with meloxicam as well as two or more crude drugs, e.g. as a Kampo medicine formulation, are combined with meloxicam. In the following preferred amounts to be given daily to an adult (in the following called "daily combination dosage") of Kampo medicine formulations comprised in an oral pharmaceutical dosage form according to this invention are specified.
The daily combination dosage of kakkon-to for an adult is usually in the range up to 25 g, preferably between 0.5 and 20 g, more preferably between 5 and 12.5 g as crude drug substance.
The daily combination dosage of keishi-to for an adult is usually in the range up to 15 g, preferably between 0.3 and 12.5 g, more preferably between 3 and 7.5 g as crude drug substance.
The daily combination dosage of kouso-san for an adult is usually in the range up to 11 g, preferably between 0.1 and 9 g, more preferably between 1.2 and 5.5 g as crude drug substance.
The daily combination dosage of saiko-keishi-to, sho-saiko-to and sho-seiryu-to for an adult is usually in the range up to 24 g, preferably between 0.4 and 18 g, more preferably between 4.8 and 12 g as crude drug substance. The daily combination dosage of bakumondo-to for an adult is usually in the range up to 30 g, preferably between 0.6 and 18 g, more preferably between 6 and 15 g as crude drug substance.
The daily combination dosage of hange-koboku-to for an adult is usually in the range up to 6 g, preferably between 0.3 and 12 g, more preferably between 3.2 and 8 g as crude drug substance.
The daily combination dosage of mao-to for an adult is usually in the range up to 13 g, preferably between 0.2 and 10 g, more preferably between 2.6 and 6.5 g as crude drug substance.
The oral pharmaceutical dosage form of the invention may be orally given in divided doses, as e.g. 2, 3 or 4 doses per day. However, the oral pharmaceutical dosage form is preferably given orally once a day. Dose adjustment of meloxicam and the crude drug may reflect age, body weight, and. manifesting symptoms.
The oral pharmaceutical dosage form described in the present invention comprises tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chewable tablets, troches, effervescent tablets, drops, suspension, fast dissolving tablets, oral fast-dispersing tablets, etc.. Any of these formulations may be prepared using regular methods, and, in addition to the aforementioned components, any additives in common use may be used upon preparation of these formulations, if necessary. In addition, preparations formed into microparticles such as microcapsules, nanocapsules, microspheres, nanospheres, may also be included in the aforementioned formulations.
In addition, further components of the oral pharmaceutical dosage form and the formulation of all ingredients are preferably chosen in view of the desired mechanical, chemical and biological stability, release rate, masking of the taste, visual appearance, etc..
For example, the pharmaceutically active substances, i.e. meloxicam or a pharmaceutically salt thereof and the second pharmaceutically active agent, can be dispensed in separate granules, multi-layer granules, multi-layer tablets or dry coated tablets, tablets of separated granules, microcapsules, etc.. Coating preparations such as sugarcoated tablets, film coating tablets, coating granule, can be used as well as chewable tablets, oral fast dispersing tablets, matrix tablets, matrix granules, effervescent tablets, dusting powder, solid solutions, etc. These methods can also be combined. Moreover, the properties of the inventive oral pharmaceutical dosage form such as stability, release, continuance, disintegration, distinglation, dissolution, concealment of taste, improvement in usage etc. can be regulated by the addition of additives known in the art.
According to a preferred embodiment the oral dosage form is a combination of a first dosage form comprising meloxicam or a pharmaceutically acceptable salt thereof and a second dosage form comprising the at least second pharmaceutically active compound. Preferably the first dosage form releases the active ingredients faster than the second dosage form. The first dosage form may further comprise the second pharmaceutically active compound and optionally further active ingredients. The second dosage form may comprise further active ingredients. Preferably the second dosage form does not comprise meloxicam.
For example the dosage form is a two layer tablet wherein the first layer comprises meloxicam or a pharmaceutical acceptable salt thereof and optionally a second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients. The second layer comprises the second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients, whereby the second layer has slow release properties compared with the first layer.
According to a further example the dosage form is a capsule comprising two kinds of granules. The first kind of granules comprise meloxicam or a pharmaceutical acceptable salt thereof and optionally a second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug , and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients. The second kind of granules comprise the second pharmaceutically active compound, as for example a vitamin, antiphlogistic agent or crude drug, and optionally further active ingredients and pharmaceutically acceptable carriers and/or excipients, whereby the second kind of granules have slow release properties compared with the first kind of granules.
These formulations may be prepared using regular methods by adding generally available pharmaceutical additives such as excipients, binders, disintegrators, lubricants, coating agents, sugar coating agents, plasticizers, antifoaming agents, polish, foaming agents, antistatic agents, desiccant, surfactant, solubilizer, buffer agents, resolvents, solubilizing agents, solvents, diluents, stabilizers, emulsifying agents, suspension, suspending agents, dispersing agents, isotonizing agents, adsorbents, reducing agents, antioxidant, wetting agents, wet modifier, filler, extender, adhesives, viscous agent, softeners, pH modifiers, antiseptics, preservatives, sweetening agents, corrigent, refrigerative agents, flavoring agents, perfume, fragrance, and coloring matters to the pharmacologically active compounds. Examples of such additives are described in Japanese Pharmaceutical Excipients Directory 2000 (edited by Japan Pharmaceutical Excipients Council, issued by Yakuji Nippo, Ltd.).
Examples of suitable pharmaceutical additives, carriers and excipients are lactose, sucrose, glucose, mannitol, xylitol, corn starch, potato starch, wheat starch, rice starch, tapioca starch, sodium carboxymethyl starch, microcrystalline cellulose, ethylcellulose, hydroxypropylmethylcellulose, low substituted hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium, carmellose, carmellose potassium, carmellose calcium, carmellose sodium, polyvinylpyrrolidone, propyleneglycol, polyethyleneglycol, glycerol, vegetable oils, waxes, crospovidone, agar, light anhydrous silicic acid, magnesium stearate, talc, titanium oxide, acacia, sodium alginate, ethanol, purified water and etc...
These preparations are preferably manufactured by adding pharmaceutical additives to the pharmacologically active compounds.
The pharmaceutical compositions and dosage forms according to this invention are advantageously usefull as analgesics, antipyretics and/or antiinflammatory agents.
The invention relates to the use of the pharmaceutical composition and of the oral pharmaceutical dosage form, both as described hereinbefore, for the treatment and alleviation of an inflammatory disease, symptoms of an inflammatory disease such as headache, toothache, ache after tooth extraction, menstrual pain, sore throat, joint pain, muscle pain, otalgia, arthralgia,. neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, traumatic pain, earache, chill, exothermic reaction and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.
Furthermore this invention relates to the use of the pharmaceutical composition and of the oral pharmaceutical dosage form, both as described hereinbefore, for the treatment and alleviation of various symptoms of common cold, for example such as fever, sore throat, chills, headache, joint, pain muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
The pharmaceutical compositions and dosage forms of the invention are effective for the treatment and alleviation of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.
In addition, this invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for the manufacture of an oral pharmaceutical dosage form according to this invention.
Thus, the invention also relates to the use of a pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs for the manufacture of an oral pharmaceutical dosage form according to this invention.
Consequently, this- invention further relates to a method of treating or alleviating of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain, in a patient in need of such treatment, which comprises orally administering to the patient a pharmaceutical composition according to this invention.
Furthermore, this invention also relates to a method of treating or alleviating of various symptoms of common cold, for example such as fever, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm in a patient in need of such treatment, which comprises orally administering to the patient a pharmaceutical composition according to this invention.
The patient to be treated according to this invention is a mammal, preferably a human.
The preferred daily' dose orally administered to the patient according to this invention is in the range of 1 to 30 mg meloxicam, more preferably 2.5 to 15 mg meloxicam, and a) in case the second pharmaceutically active compound is one or more vitamins, an amount of 0.1 to 2000 mg, more preferably 0.1 to 500 mg, of the one or more vitamins; b) in case the second pharmaceutically active compound is one or more antiphlogistic agents, an amount of 1 to 2000 mg, more preferably 3 to 750 mg, of the one or more antiphlogistic agents; c) in case the second pharmaceutically active compound is one or more crude drugs, an amount of of 0.001 to 20 g, more preferably 0.002 to 10 g, of the one or more crude drugs.
The preferred doses regarding the various second pharmaceutically active compounds were specified above. Therefore, the amount of the dosage form to be taken by a patient per day, i.e. the number of tablets, capsules, caplets, troches, etc., or the amount of granules, syrup, solution, suspension, etc., e.g. measured in grams or milliliters, is such that the above specified preferred daily dose is achieved.
Meloxicam or a pharmaceutically acceptable salt thereof and the at least one pharmaceutically active compound are preferably combined in a single oral dosage form as described above. Both, meloxicam or a salt thereof and the at least one pharmaceutically active compound may also be simultaneously administered in two separate oral dosage forms, one containing meloxicam or a salt thereof and the other containing the second pharmaceutically active compoundvitamin.
The compositions and dosage forms of the present invention are explained by the following examples which however do not limit the scope of the present invention. The examples 1.1 to 1.6 illustrate the first embodiment of the present invention, the examples 2.1 to 2.6 illustrate the second embodiment of the present invention and the examples 3.1 to 3.6 illustrate the third embodiment of the present invention.
Examples
Example 1.1 Tablet The following ingredients are homogeneously mixed. The resulted mixed particles are compressed with a mold to prepare 250 mg-tablets. Meloxicam 45 g Bisbentiamine 60 g Riboflavin 36 g Hesperidin 120 g Lactose 603 g Microcrystalline cellulose 606 g Light anhydrous silicic acid 15 g Magnesium stearate 9 g Talc 6 g
Example 1.2 Powder
The following ingredients are homogeneously mixed. The resulted mixed particles are divided into 750 mg per portion. Meloxicam 15 g Ascorbic acid 1000 g Corn starch 400 g Lactose 70 g Magnesium stearate 15 g
Example 1.3 Two layer tablet
The following ingredients of layer A and layer B are prepared by a regular method to provide mixed particles, and the particles are compressed to form 320 mg of two layer tablet (layer A 100 mg, layer B 220 mg).
Layer A: Meloxicam 15 g Thiamine hydrochloride 20 g Riboflavin sodium phosphate 4 g Allylisopropylacetylurea 120 g Anhydrous caffeine 160 g Lactose 135 g Microcrystalline cellulose 134 g Light anhydrous silicic acid . 4 g Sodium lauryl sulfate 4 g Talc 2 g Magnesium stearate 2 g Layer B: Allylisopropylacetylurea 240 g Anhydrous caffeine 320 g Lactose 66 g Fu marie acid 100 g Succinic acid 40 g Hydroxypropylmethylcellulose 2208 180 g Hydrogenated oil 120 g Stearic acid 120 g Glycerol esters of fatty acids 120 g Magnesium stearate 14 g
Example 1.4
Granules
The following ingredients are prepared as granules by a regular method to prepare mixed particles. The granules are packed in amounts of 1000 mg.per pack. Meloxicam 15 g Riboflavin 24 g Hesperidin 60 g Calcium carboxymethylcellulose 240 g Mannitol 1332 g Corn starch 307 g Aspartame 10 g Acesulfame potassium 10 g Fragrant materials 2 g
Example 1.5 Film-coating tablet
The following ingredients are prepared by a regular method to provide mixed particles, and the particles are compressed to form 175 mg-tablets. Meloxicam 45 g Thiamine nitrate 24 g Riboflavin 24 g Lactose 453 g Microcrystalline cellulose 720 g Corn starch 480 g Low substituted hydroxypropylcellulose 180 g Hydroxypropylcellulose 120 g Light anhydrous silicic acid 18 g Talc 24 g Magnesium stearate 12 g
Subsequently, the tablets are transferred into a coating pan, and are coated using the equal volume mixture of ethyl alcohol contained 5% weight/volume of hydroxypropylmethylcellulose and purified water to increase in weight/volume by 5 mg per one tablet. Thus film-coating tablets are prepared.
Example 1.6
Capsules
The following ingredients are prepared as granules by regular methods, and filled into capsules, whereby the amount per capsule is 150 mg. Meloxicam 60 g Thiamine nitrate 8 g Riboflavin 16 g Ascorbic acid 400 g Hesperidin 144 g Allylisopropylacetylurea 480 g Anhydrous caffeine 240 g Mannitol 296 g Microcrystalline cellulose 756 g
Example 2.1
Two layer tablet
The following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 300 mg (layer A 100 mg, layer B 200 mg) each. Layer A: Meloxicam 15 g Tranexamic acid 280 g Anhydrous caffeine 160 g Lactose 95 g Microcrystalline cellulose 230 g Sodium lauryl sulfate 6 g Light anhydrous silicic acid 6 g Talc 4 g Magnesium stearate 4 g Layer B: Tranexamic acid 560 g Anhydrous caffeine 320 g Lactose 84 g Fumaric acid 100 g Succinic acid 100 g Hydroxypropylmethylcellulose 2208 100 g Hydrogenated oil 160 g Stearic acid 80 g Glycerol esters of fatty acids 80 g Magnesium stearate 16 g
Example 2.2 Two layer tablet
The following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 310 mg (layer A 110 mg, layer B 200 mg) each. Layer A: Meloxicam 45 g Semi-alkaline proteinase 60. g Diphenhydramine hydrochloride 150 g Ambroxol hydrochloride 90 g Dihydrocodeine phosphate 48 g dl-Methylephedrine hydrochloride 120 g Anhydrous caffeine 150 g Lactose 492 g Microcrystalline cellulose 768 g Sodium lauryl sulfate 18 g Light anhydrous silicic acid 18 g Talc 12 g Magnesium stearate 9 g Layer B: Diphenhydramine hydrochloride 300 g Ambroxol hydrochloride 180 g Dihydrocodeine phosphate 96 g dl-methylephedrine hydrochloride 240 g Anhydrous caffeine 300 g Lactose 468 g Fumaric acid 300 g Succinic acid 60 g Hydroxypropylmethylcellulose 2208 540 g Hydrogenated oil 360 g Stearic acid 360 g Glycerol esters of fatty acids 360 g Magnesium stearate 36 g
Example 2.3 Granules
The following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1300 mg per one pack of granules. Meloxicam 37.5 g Bromelain 500.0 g Clemastine fumarate 6.7 g Dihydrocodeine phosphate 40.0 g dl-Methylephedrine hydrochloride 100.0 g Bromhexine hydrochloride 20.0 g Anhydrous caffeine 250.0 g Magnesium carbonate 500.0 g Calcium carboxymethylcellulose 500.0 g Mannitol 3500.0 g Corn starch 990.8 g Aspartame 25.0 g Acesulfame potassium 25.0 g Fragrant materials 5.0 g
Example 2.4
Capsules
The following ingredients are prepared as fast release granules and slow release granules through regular methods, and capsule-filled to give an amount of 285 mg
(fast release granules: 90 mg, delayed release granules: 15 mg, slow release granules: 180 mg) per one capsule.
Fast release granules: Meloxicam 60.0 g Triprolidine hydrochloride 9.6 g Tipepidine hibenzate 160.0 g dl-Methylephedrine hydrochloride 160.0 g Anhydrous caffeine 240.0 g Microcrystalline cellulose 810.4 g Delayed release granules: Serrapeptase 40.0 g Microcrystalline cellulose 160.0 g Hydroxypropylmethylcellulose phthalate (coating layer) 36.0 g Glycerol esters of fatty acids (coating layer) 3.2 g Talc (coating layer) 0.8 g Slow release granules: Triprolidine hydrochloride 19.2 g Tipepidine. hibenzate 320.0 g dl-Methylephedrine hydrochloride 320.0 g Anhydrous caffeine 480.0 g Fumaric acid 288.0 g Microcrystalline cellulose 1236.8 g Ethylcellulose (coating layer) 136.0 g Hydroxypropylmethylcellulose (coating layer) 24.0 g Glycerol esters of fatty acids (coating layer) 44.0 g Talc (coating layer) 12.0 g
Example 2.5
Capsules
The following ingredients are prepared as fast release granules and slow release granules through regular methods, and capsule-filled to give an amount of 365 mg
(fast release granules: 115 mg, delayed release granules: 15 mg, slow release granules: 235 mg) per one capsule.
Fast release granules: Meloxicam 60.0 g Isothipendyl hydrochloride 24.0 g Guaifenesin 666.4 g dl-Methylephedrine hydrochloride . 160.0 g Anhydrous caffeine 200.0 g Microcrystalline cellulose 729.6 g Delayed release granules: Semi-alkaline proteinase 80.0 g Microcrystalline cellulose 120.0 g Methacrylic acid copolymer LD (coating layer) 28.8 g Macrogol 6000 (coating layer) 3.2 g Talc (coating layer) 8.0 g Slow release granules: Isothipendyl hydrochloride 32.0 g Guaifenesin 1333.6 g dl-Methylephedrine hydrochloride 320.0 g Anhydrous caffeine 400.0 g Fumaric acid 400.0 g Microcrystalline cellulose 762.4 g Methacrylic acid copolymer S (coating layer) 360.0 g Glycerol esters of fatty acids (coating layer) 104.0 g Talc (coating layer) 48.0 g
Example 2.6 Granules
The following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1500 mg per one pack of granules.
Meloxicam 37.5 g Serrapeptase 75.0 g Tranexamic acid 1250.0 g Clemastine fumarate 6.7 g Dihydrocodeine phosphate 40.0 g dl-Methylephedrine hydrochloride 100-° 9 Ambroxol hydrochloride 75.0 g Anhydrous caffeine 250.0 g Magnesium carbonate 500.0 g Calcium carboxymethylcellulose 500.0 g Mannitol 4000.0 g Corn starch 610.8 g Aspartame 25.0 g Acesulfame potassium 25.0 g Fragrant materials 5.0 g Example 3.1 Granules
The following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1400 mg per one pack of granules.
Meloxicam 15 g Earthworm extract 260 g (extract of 2 kg Earthworm)
Peony root extract 200 g (extract of 2 kg Peony root) Glycyrrhiza extract 400 g (extract of 2 kg Glycyrrhiza) Calcium carboxymethylcellulose 240 g Mannitol 1400 g Corn starch 220 g Light anhydrous silicic acid 42 g Aspartame 10 g Acesulfame potassium 10 g Fragrant materials 3 g
Example 3.2 Granules
The following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1500 mg per one pack of granules.
Meloxicam 15 g Kakkon-to extract 1200 g (extract of Pueraria root 2.4 kg, ephedra herb 1.2 kg, jujube 1.2 kg, cinnamon bark 0.9 kg, peony root 0.9 kg, glycyrrhiza 0.6 kg, ginger 0.3 kg) Dihydrocodeine phosphate - 16 g Chlorpheniramine maleate 5 g Anhydrous caffeine 100 g Calcium carboxymethylcellulose 200 g Mannitol 1179 g Corn starch 220 g Light anhydrous silicic acid 42 g Aspartame 10 g Acesulfame potassium 10 g Fragrant materials 3 g
Example 3.3
Two layer tablet
The following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablets at 400 mg (layer A 200 mg, layer B 200 mg) each. Layer A: Meloxicam 15 g Japanese valerian extract 320 g (extract of 1.2 kg Japanese valerian) Allylisopropylacetylurea 120 g Anhydrous caffeine 120 g Lactose 161 g Microcrystalline cellulose 440 g Sodium lauryl sulfate 6 g Light anhydrous silicic acid 6 g Talc 8 g Magnesium stearate 4 g Layer B: Allylisopropylacetylurea 240 g Anhydrous caffeine 240 g Lactose 68 g Fumaric acid 120 g Hydroxypropylmethylcellulose 2208 180 g Hydrogenated oil 120 g Stearic acid 120 g Glycerol, esters of fatty acids 120 g Magnesium stearate 12 g
Example 3.4
Two layer tablet
The following ingredients of the layer A and the layer B are processed through a regular method to provide mixed particles, respectively, and the particles are compressed to form two layer tablet at 270 mg (layer A 130mg, layer B 140mg) each. Layer A: Meloxicam '15 g Ginseng extract 200 g (extract of 2.9 kg Ginseng) Gentian extract 40 g (extract of 0.4 kg Gentian) Isothipendyl hydrochloride 5 g Ambroxol hydrochloride 30 g Dihydrocodeine phosphate 16 g dl-Methylephedrine hydrochloride 40 g Anhydrous caffeine 50 g Lactose . 92 g Microcrystalline cellulose 270 g Sodium lauryl sulfate 6 g Light anhydrous silicic acid 8 g Talc 4 g Magnesium stearate 4 g Layer B: Isothipendyl hydrochloride 9 g Ambroxol hydrochloride 60 g Dihydrocodeine phosphate 32 g dl-Methylephedrine hydrochloride 80 g Anhydrous caffeine 100 g Lactose 75 g Fumaric acid 70 g Hydroxypropylmethylcellulose 2208 136 g Hydrogenated oil 90 g Stearic acid 90 g Glycerol esters of fatty acids 90 g Magnesium stearate 8 g
Example 3.5 Granules
The following ingredients are prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 1800 mg per one pack of granules. Meloxicam 7.50 g Saiko-keishi-to extract 720.00 g (extract of Glycyrrhiza 0.4kg, cinnamon bark 0.6kg, peony root 0.6kg, ginger 0.2kg, ginseng 0.4kg, scutellaria root 0.2kg, bupleurum root 1 kg, jujube 0.4kg, pinellia tuber 0.8kg) Clemastine fumarate 1 -34 g Tipepidine hibenzate 20.00 g Anhydrous caffeine 50.00 g Calcium carboxymethylcellulose 120.00 g Mannitol 730.00 g Corn starch 107.36 g Light anhydrous silicic acid 24.00 g Aspartame 9.00 g Acesulfame potassium 9.00 g Fragrant materials 1.80 g
Example 3.6 Capsules The following ingredients are prepared as fast release granules and slow release granules through regular methods, and capsule-filled to give an amount of 300 mg
(fast release granules: 120 mg, slow release granules: 180 mg) per one capsule. Fast release granules: Meloxicam 60 g Powdered oriental bezoar 24 g Epinastine hydrochloride 80 g Ambroxol hydrochloride 120 g Dihydrocodeine phosphate 64 g f/"-MethyIephedrine hydrochloride 160 g Noscapine 128 g Anhydrous caffeine 200 g Lysozyme hydrochloride 240 g Bisibutiamine 96 g Riboflavin 48 g Corn starch 160 g Hydroxypropylcellulose 40 g Microcrystalline cellulose 500 g Slow release granules: Ambroxol hydrochloride 240 g Dihydrocodeine phosphate 128 g dl-Methylephedrine hydrochloride 320 g Noscapine 256 g Anhydrous caffeine 400 g Fumaric acid 336 g Corn starch 200 g Hydroxypropylcellulose 48 g Microcrystalline cellulose 752 g Ethylcellulose (coating layer) 120 g Hydroxypropylmethylcellulose (coating layer) 24 g Glycerol esters of fatty acids (coating layer) 40 g Talc (coating layer) 16 g

Claims

Claims
1. A pharmaceutical composition comprising meloxicam or a pharmaceutically acceptable salt thereof and a second pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs.
2. The pharmaceutical composition according to claim 1 comprising meloxicam or a pharmaceutically acceptable salt thereof and one or more vitamins.
3. The pharmaceutical composition according to claim 1 comprising meloxicam or a pharmaceutically acceptable salt thereof and one or more antiphlogistic agents.
4. The pharmaceutical composition according to claim 1 comprising meloxicam or a pharmaceutically acceptable salt thereof and one or more crude drugs.
5. The pharmaceutical composition according to claim 3 further comprising at least one vitamin.
6. The pharmaceutical composition according to claim 4 further comprising at least one vitamin.
7. The pharmaceutical composition according to claim 4 or 6 further comprising at least one antiphlogistic agent.
8. The pharmaceutical composition according to one of the claims 3 to 7 further comprising at least one anti-H1-histamine.
9. The pharmaceutical composition according to one or more of the previous claims further comprising one or more other pharmacologically active substances selected from the group consisting of antacids, sedatives, central nervous system stimulants, antitussive agents and expectorants.
10. The pharmaceutical composition according to one or more of the previous claims further comprising at least one pharmaceutically acceptable carrier and/or excipient.
11. The pharmaceutical composition according to one or more of the previous claims, wherein the vitamin is selected from the group consisting of vitamin B1 , vitamin B2, vitamin C and/or hesperidin, including salts and derivatives thereof.
12. The pharmaceutical composition according to claim 11 , wherein the vitamin is selected from the group consisting of thiamine, thiamine hydrochloride, - thiamine nitrate, thiamine disulfide nitrate, thiamine disulfide, thiamine dicetylsulfate salt, dicethiamine hydrochloride, fursultiamine hydrochloride, fursultiamine, octotiamine, cycotiamine, bisibutiamine, bisbentiamine, prosultiamine, benfotiamine, cocarboxylase, dibenzoylthiamaine, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, flavin adenine dinucleotide, ascorbic acid, sodium ascorbate, calcium ascorbate, hesperidin and alpha G hesperidin.
13. The pharmaceutical composition according to one or more of the previous claims, wherein the one or more antiphlogistic agents are selected from the group consisting of semi-alkaline proteinase, serrapeptase, bromelain and tranexamic acid.
14. The pharmaceutical composition according to one or more of the previous claims, wherein the one or more crude drugs are selected from the group consisting of earthworm, cinnamon bark, peony root, moutan bark, Japanese valerian, zanthoxylum fruit, ginger, citrus unshiu peel, fennel, phellodendron bark, coptis rhizome, zedoary, German chamomile, gentian, oriental bezoar, bear bile, foϋrleaf ladybell root, atractylodes lancea rhizome, clove, atractylodes rhizome, panax rhizome, ginseng, scutellaria root, pueraria root, apricot kernel, cyperus rhizome, rice, magnolia bark, schisandra fruit, bupleurum root, asiasarum root, perilla herb, jujube, ophiopogon tuber, pinellia tuber and poria sclerotium.
15. The pharmaceutical composition according to one or more of the previous claims, wherein the crude drug is selected from the group of Kampo medicine formulations consisting of kakkon-to, keishi-to, kouso-san, saiko-keishi-to, sho-saiko-to, sho-seiryu-to, bakumondo-to, hange-koboku-to and mao-to.
16. The pharmaceutical composition according to one or more of the previous claims, wherein the crude drug is in the form of a dried powder, an extract, a fluidextract, a tincture or an oil
17. An oral pharmaceutical dosage form comprising a pharmaceutical composition according to one or more of the claims 1 to 16.
18. The oral pharmaceutical dosage form according to claim 17 wherein the amount of meloxicam or a pharmaceutically acceptable salt thereof is in the range of 1 to 30 mg.
19. The oral pharmaceutical dosage form according to claim 17 or 18 wherein the amount of the second pharmaceutically active compound is: a) in the range from 0.1 to 2000 mg in case the second pharmaceutically active compound is one or more vitamins; b) in the range from 1 to 2000 mg in case the second pharmaceutically active compound is one or more antiphlogistic agents; c) in the range from 0.001 to 20 g in case the second pharmaceutically active compound is one or more crude drugs.
20. Use of an oral pharmaceutical dosage form according to one or more of the claims 17 to 19 as an anti-inflammatory, analgesic and/or antipyretic agent.
21. Use of an oral pharmaceutical dosage form according to one or more of the claims 17 to 19 for the treatment or alleviation of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as fever, pyrexia, arthralgia, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm.
22. A method of treating or alleviating of an inflammatory disease, symptoms of an inflammatory disease, headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction, fever and/or cold and various symptoms of cold such as fever, pyrexia, arthralgia, sore throat, chills, headache, joint pain, muscular pain, runny nose, stuffy nose, sneezing, cough and phlegm, in a patient in need of such treatment, which comprises orally administering to the patient a pharmaceutical composition according to one or more of the claims 1 to 16.
23. The method according to claim 22 characterized by orally administering to the patient an amount of 1 to 30 mg of meloxicam or a pharmaceutically acceptable salt thereof and a) in case the second pharmaceutically active compound is one or more vitamins, an amount of 0.1 to 2000 mg of one or more vitamins; b) in case the second pharmaceutically active compound is one or more antiphlogistic agents, an amount of 1 to 2000 mg of one or more antiphlogistic agents; c) in case the second pharmaceutically active compound is one or more crude drugs, an amount of 0.001 to 20 g of one or more crude drugs.
24. Use of meloxicam or a pharmaceutically acceptable salt thereof for the manufacture of an oral pharmaceutical dosage form according to one or more of the claims 17 to 19.
5. Use of a pharmaceutically active compound selected from the group consisting of vitamins, antiphlogistic agents and crude drugs, for the manufacture of an oral pharmaceutical dosage form according to one or more of the claims 17 to 19.
PCT/EP2005/005747 2004-06-04 2005-05-28 Compositions comprising meloxicam WO2005117895A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007513820A JP2008501655A (en) 2004-06-04 2005-05-28 Meloxicam-containing composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04013217.7 2004-06-04
EP04013217 2004-06-04
EP04014409.9 2004-06-19
EP04014410.7 2004-06-19
EP04014409 2004-06-19
EP04014410 2004-06-19

Publications (3)

Publication Number Publication Date
WO2005117895A2 true WO2005117895A2 (en) 2005-12-15
WO2005117895A8 WO2005117895A8 (en) 2006-05-18
WO2005117895A3 WO2005117895A3 (en) 2006-08-17

Family

ID=34969355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005747 WO2005117895A2 (en) 2004-06-04 2005-05-28 Compositions comprising meloxicam

Country Status (2)

Country Link
JP (1) JP2008501655A (en)
WO (1) WO2005117895A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182400A (en) * 2006-01-06 2007-07-19 Nichi-Iko Pharmaceutical Co Ltd Meloxicam-containing tablet composition having excellent stability with time
WO2007144323A2 (en) * 2006-06-15 2007-12-21 Alpex Pharma Sa Solid forms containing meloxicam with improved taste and process for their preparation
JP2009007311A (en) * 2007-06-29 2009-01-15 Lintec Corp Diphenhydramine-acesulfame adduct, method for producing the same and oral preparation containing the adduct
CN103239706A (en) * 2013-05-13 2013-08-14 肖梅芬 Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof
CN103263660A (en) * 2013-05-13 2013-08-28 肖梅芬 Earthworm protein for reducing blood sugar and blood pressure and eliminating diabetic complications and application pf earthworm protein
CN104491814A (en) * 2014-12-30 2015-04-08 兰州古驰生物科技有限公司 Traditional Chinese medicine preparation for conditioning sensation of chill and intolerance of cold
CN104524170A (en) * 2014-12-26 2015-04-22 丁鸿磊 Traditional Chinese medicine for treating wind-fire toothache and preparation method thereof
CN104586979A (en) * 2015-01-17 2015-05-06 塔里木大学 Cough-relieving oral liquid and preparation method thereof
CN108143906A (en) * 2018-02-26 2018-06-12 威海惠高生物科技有限公司 It is a kind of to hinder the Chinese medicine composition coughed and preparation method for treating phlegm

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5823746B2 (en) * 2010-06-30 2015-11-25 興和株式会社 Pharmaceutical composition
CN102614344B (en) * 2012-01-13 2013-12-25 李玉芹 Traditional Chinese medicine for treating qi-blood deficiency periodontitis, preparation method and administration method thereof
CN103301247B (en) * 2013-07-09 2014-12-10 华菊 Traditional Chinese medicine composition for treating chronic nephritis and preparation method thereof
CN104491484A (en) * 2014-12-06 2015-04-08 唐云峰 Traditional Chinese medicine composition for treating kidney deficiency and liver-yang hyperactivity
CN106983801A (en) * 2017-05-31 2017-07-28 邹圣余 It is a kind of to be used to treat medicine of fracture and preparation method thereof
CN108079051A (en) * 2018-01-13 2018-05-29 上海欧润化妆品有限公司 A kind of Radix Gentianae extract and its extraction process
JP7209537B2 (en) * 2018-02-23 2023-01-20 ライオン株式会社 Solid pharmaceutical formulation
JP2019142860A (en) * 2018-02-23 2019-08-29 ライオン株式会社 Pharmaceutical composition and pharmaceutical preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
WO2003070251A1 (en) * 2002-02-19 2003-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2005016243A2 (en) * 2003-06-09 2005-02-24 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH083066A (en) * 1994-06-20 1996-01-09 Takeda Chem Ind Ltd Therapeutic drug for cold
JP2001247481A (en) * 2000-03-06 2001-09-11 Taisho Pharmaceut Co Ltd Medicinal composition
MXPA04007536A (en) * 2002-02-04 2004-11-10 Pharmacia Corp Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof.
WO2005094832A1 (en) * 2004-04-01 2005-10-13 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
WO2003070251A1 (en) * 2002-02-19 2003-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2005016243A2 (en) * 2003-06-09 2005-02-24 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Vitamin E as an alternative for nonsteroid antiinflammatory agents in the therapy of rheumatic disease" DEUTSCHE APOTHEKER ZEITUNG 1993 GERMANY, vol. 133, no. 24, 1993, page 68+70, XP001207064 ISSN: 0011-9857 *
BERMOND P: "Analgesic and antiinflammatory properties of vitamins." INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH. SUPPLEMENT = INTERNATIONALE ZEITSCHRIFT FUR VITAMIN- UND ERNAHRUNGSFORSCHUNG. SUPPLEMENT. 1989, vol. 30, 1989, pages 153-160, XP009052334 ISSN: 0373-0883 *
ENGELHARDT G: "PHARMACOLOGY OF MELOXICAM, A NEW NON-STEROIDAL ANTI-INFLAMMATORY DRUG WITH AN IMPROVED SAFETY PROFILE THROUGH PREFERENTIAL INHIBITION OF COX-2" BRITISH JOURNAL OF RHEUMATOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 35, no. SUPPL 1, 1 April 1996 (1996-04-01), pages 4-12, XP000603408 ISSN: 0263-7103 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182400A (en) * 2006-01-06 2007-07-19 Nichi-Iko Pharmaceutical Co Ltd Meloxicam-containing tablet composition having excellent stability with time
WO2007144323A2 (en) * 2006-06-15 2007-12-21 Alpex Pharma Sa Solid forms containing meloxicam with improved taste and process for their preparation
EP1870102A1 (en) * 2006-06-15 2007-12-26 Alpex Pharma SA Solid forms containing meloxicam with improved taste and process for their preparation
WO2007144323A3 (en) * 2006-06-15 2008-03-13 Alpex Pharma Sa Solid forms containing meloxicam with improved taste and process for their preparation
US10016359B2 (en) 2006-06-15 2018-07-10 Alpex Pharma Sa Solid forms containing meloxicam with improved buccal taste and process for their preparation
JP2009007311A (en) * 2007-06-29 2009-01-15 Lintec Corp Diphenhydramine-acesulfame adduct, method for producing the same and oral preparation containing the adduct
CN103263660A (en) * 2013-05-13 2013-08-28 肖梅芬 Earthworm protein for reducing blood sugar and blood pressure and eliminating diabetic complications and application pf earthworm protein
CN103239706B (en) * 2013-05-13 2014-11-26 肖梅芬 Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof
CN103239706A (en) * 2013-05-13 2013-08-14 肖梅芬 Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof
CN104524170A (en) * 2014-12-26 2015-04-22 丁鸿磊 Traditional Chinese medicine for treating wind-fire toothache and preparation method thereof
CN104491814A (en) * 2014-12-30 2015-04-08 兰州古驰生物科技有限公司 Traditional Chinese medicine preparation for conditioning sensation of chill and intolerance of cold
CN104586979A (en) * 2015-01-17 2015-05-06 塔里木大学 Cough-relieving oral liquid and preparation method thereof
CN108143906A (en) * 2018-02-26 2018-06-12 威海惠高生物科技有限公司 It is a kind of to hinder the Chinese medicine composition coughed and preparation method for treating phlegm

Also Published As

Publication number Publication date
JP2008501655A (en) 2008-01-24
WO2005117895A8 (en) 2006-05-18
WO2005117895A3 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
WO2005117895A2 (en) Compositions comprising meloxicam
US5629316A (en) Stabilized solid pharmaceutical preparation and method of producing the same
WO2005094832A1 (en) Compositions comprising meloxicam
CN1293867C (en) Drug preparations
CN1520292A (en) Medicinal compsns.
TW201247195A (en) Stable pharmaceutical composition
WO2005004915A2 (en) Compositions comprising meloxicam
US5739165A (en) Stabilized solid pharmaceutical preparation and method of producing the same
WO2021109511A1 (en) Anti-fatigue composition and preparation method therefor
US20050038018A1 (en) Meloxicam compositions
JPH06287144A (en) Pharmaceutical preparation for common cold
JP2008247822A (en) Analgesic composition
JP4052603B2 (en) Formulation for oral administration
JP2006506407A (en) Novel pharmaceutical composition containing ambroxol and iodopropamide iodide
JPH083066A (en) Therapeutic drug for cold
JPH0797325A (en) Stable solid pharmaceutical and its production
JP3987501B2 (en) Pharmaceutical composition
JP2021017445A (en) Pharmaceutical composition containing fexofenadine
JP2010241834A (en) Pharmaceutical composition
JP2005289906A (en) Medicinal composition
JP5241127B2 (en) Analgesic composition
JP2018076312A (en) Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components
US20040259955A1 (en) New pharmaceutical compositions containing ambroxol and isopropamide iodide
JP2005289905A (en) Medicinal composition
TW202412752A (en) Solid preparation and method for producing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 50/2005 UNDER (71 APPLICANT BOEHRINGER INGELHEIM INTERNATIONAL GMBH) REPLACE "DESIGNATIONS" BY "CORRECT DESIGNATIONS"

WWE Wipo information: entry into national phase

Ref document number: 2007513820

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase